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Abstract 
Age-related macular degeneration (AMD) is a leading cause of severe visual 
impairment affecting about 1.5% of most populations worldwide. It is a late-onset, 
chronic and progressive degenerative disorder involving typical lesions in the 
macular and choroids of the eye leading to the loss of central vision. The late stage of 
AMD with visual loss is classified into two major subtypes, geographic atrophy and 
exudative AMD. Exudative AMD is characterized by choroidal neovascularization 
and occurs in 10% of AMD patients, accounting for more than 90% of blindness 
caused by the disease. Epidemiologic studies show that exudative AMD with no soft 
indistinct drusens that are characteristics of dry AMD is more prevalent in Asian 
populations. The etiology of AMD is complex, attributed to multiple genetic and 
environmental factors. Linkage studies have mapped AMD to 2 chromosomal loci, 
lq32 and 10q26. In 2005，a genome-wide association study revealed Y402H-CFH 
mapped to chromosome lq32 as an AMD-susceptible variant. But follow-up studies 
found no association between Y402H-CFH and AMD in Chinese and Japanese 
populations. 
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To identify genetic variant(s) that predisposes individuals to the predominant 
exudative AMD phenotype in the Chinese population, a genome-wide association 
study was conducted. Positional cloning was then performed on the most prominent 
gene lying in close proximity of the genetic variant(s) identified to further 
characterize the critical genetic factors linked to the disease. 
In a genome-wide SNP scanning and linkage disequilibrium association study with 
96 AMD patients and 130 unrelated control subjects, a new genetic variant, 
rs10490924, located on chromosome 10q26 was identified. It increased the risk of 
exudative AMD with an extremely high OR of 11.1 and attributed to the population 
with large associated PAR of 84%, suggesting a high impact to the disease, 
rs10490924 lies in a hypothetical gene, LOC387715, with no evidence of biological 
function. It resides between PLEKHA1 and HTRA1. The frequency of the rare allele 
at PLEKHA1 showed no association with AMD. Hence, the other gene, HTRA1, was 
further investigated. 
A case-control study involving 163 exudative AMD patients and 183 unrelated 
control subjects revealed 4 significant SNPs in the promoter and the first exon of 
HTRA1: -491G>A (rsl 1200638), -359T>C (rs2672598), 230C>T (rsl049331) and 
236G�T (rs2293870) with respective p-values = 5.9 x 10"14, 5.0 x 10"12, 1.1 x 10'13 
and 1.1 x 10"13. Among them, rsl 1200638 (-491G�A) is the most significant 
associated SNP with a very high OR of 7.64 (95%CI: 3.98-14.65). Association of 
this SNP with eye disease has not been previously reported. Interactive analyses of 
rsl 1200638 with smoking and with rs800292 (CFH) were conducted. Independent 
multiplicative effects without significant interaction in either model were found. The 
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joint disease OR of smoking and rs11200638 {HTRA1) caused a 15.71 fold increase 
in risk whereas that of rs800292 (CFH) and rsl 1200638 showed a 23.3 fold 
increased risk. An extremely high PAR of 78.4% was also found, indicating a high 
impact of the additive effect of CFH and HTRA1 in the development of exudative 
AMD. A new AMD-susceptible //77^47variant was therefore identified in this study 


















wide association)，把濕性老年黃斑病變定位在染色體10q26的rs 10490924 
上，這個危險因子會大大提高致11.1，而族群相差危險性百分比(PAR)爲 





(SNP): -491G�A (rsl 1200638), -359T>C (rs2672598), 230C>T (rsl049331)和 
236G>T (rs2293870)，它們分別的 p-value 爲 5.9xl(T14，5.0xl012, l.lxlO"13 和 
丨 l . l x l O 1 3 � r s l 1200638 所引致的病例對照 OR是最大的（OR=7.64; 95%CI: 3.98-
14.65)�相互作用之硏究發現吸煙和rs8002% C 跟 r s l 1200638 (i /m47)皆 
沒有相互作用，它們和 r s l 1200638之關係爲獨立性的乘積性作用。吸煙和 
rsl 1200638 (HTRA1)之聯合疾病 OR 爲 15.71 ；而 rs8002% (CFH)和 
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Age-related macular degeneration (AMD) is a leading cause of severe visual impairment 
in the United States, Europe and most developed countries, affecting more than 10 
million people worldwide (Friedman et al.，2004;la Cour M. et al., 2002). It is a late-
onset, chronic and progressive degenerative disorder involving typical lesions in the 
central region of the retina (macula) and choroid leading to loss of central vision (Figure 
1.1). Light enters the eye through the pupil, which is then focused on the back of the eye 
(retina) by the cornea and the lens located behind the pupil (Figure 1.2). The retina is the 
light-sensitive nerve layer lining at the back of the eye. Electric impulses are then 
created and transmitted through the optic nerve to the brain. The macula is the center of 
the retina, comprising approximately 20% of the total population of cone photoreceptors 
and a markedly increased density of ganglion cells (Curcio and Allen, 1990). Fovea 
situated in the center of the macula has the peak concentration of cone photoreceptors. 
The macula together with the fovea is responsible for fine detail image. AMD, being a 
progressive disease of the retina, attacks the macula giving rise to central blurred vision 
or central vision loss (Figure 1.3) but with preservation of peripheral visual field. Its 
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Figure 1.1. Anatomy of the Eye. 
The macula is situated in the central region of the retina with fovea approximately in its 
centre. 
(Picture is obtained from online database, MD Support, Inc. & the National Low Vision 
Support Group. 
http ://www .mdsupport.org/index.html) 
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Figure 1.2 Layers of the retina and the choroid 
(Picture is obtained and modified from online database, MD Support, Inc. & the 
National Low Vision Support Group, 
http ://www.mdsupport.org/ anatomy.html) 
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Figure 1.3 Visual field loss in AMD patients 
Left: Wavy and crooked image at the center of vision experienced by patients. 
Right: Central vision loss with peripheral image undisturbed. 
(Photos are obtained from online database, The Macular Degeneration Partnership. 
http://www.amd.org/site/PageServer?pagename=Vision—Examples) 
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clinical and pathological features are alteration of retinal pigment epithelium (RPE) cells 
and Bruch's membrane, drusen formation, hypo and/or hyperpigmentation, loss of 
photoreceptors, choroidal neovascularization, and subretinal fibrous and/or neovascular 
tissue in the macula (Ambati et al.，2003). 
1.2. Epidemiology 
AMD has a prevalence of 9% of the total population from the group of age 52 to 85 
years (Bonastre et al., 2002; Haddad et al, 2006; Klein et al, 2006). It has been reported 
that about 30% of the population over 75 years of age harbor some degree of AMD 
(Friedman et al., 2004;Klein et al., 1992;Oneill et al., 2001). Approximately 6-8% of this 
group will advance to the later stage of the disease, which causes the most severe visual 
loss. Atrophic AMD and exudative AMD are the two forms of advanced forms of AMD, 
with atrophic AMD being the most prevalent form (85% of AMD cases). Although 
exudative AMD is less common, it poses more threats to vision loss. Among these 
severe cases, nearly 90% are due to the suffer of exudative/wet AMD (Bylsma and 
Guymer, 2005;Donoso et al., 2006). With the growth of the elderly population, 
particularly in the developed countries, the incidence of the disease will be expected to 
increase by 50% (Friedman et al., 2004;Smith et al., 2001). It is of utmost importance to 
unravel the etiology of AMD so as to prevent or eliminate the threatening of visual 
impairment and to ease the burden to public health. 
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1.3. Classification 
Early AMD is characterized by the presence of soft drusen with no loss of visual acuity. 
It is advanced to the later stage of AMD with visual loss and is broadly classified into 
two clinical forms, namely dry AMD or geographic atrophy and wet or neovascular or 
exudative AMD. These two clinical forms are further subdivided, according to their 
specific phenotypic characteristics, to five-step grading systems with geographic atrophy 
and exudative AMD being the advanced stages (Table 1.1) (Bird et al.，1995;Friedman 
et al” 2004;Klein et al” 1991;Seddon et al” 2006c). Exudative AMD is known to be the 
more severe form. 
1.3.1. Dry AMD 
Dry AMD is the most abundant form of AMD that comprises about 80% of the cases. 
Drusen are its characteristic feature which are yellow, extracellular deposits of lipid, 
protein and cellular debris formed subretinally between the Bruch's membrane and the 
RPE, a layer with photoreceptor cells (Figure 1.4) (Mullins et al., 2000;Russell et al., 
2000;Wang et al., 2003). They have been reported to contain complement proteins and 
inflammatory modulators generated by inflammation (Anderson et al., 2002;Hageman et 
al., 2001;Hageman et al., 2005;Mullins et al., 2000). Hyperpigmentation or 
hypopigmentation are observed abnormalities in RPE. Large drusens form from 
coalescent may lead to RPE detachment. Some of these lesions progress to atrophic area 
causing geographic atrophy (GA), which is one of the advanced forms of AMD with 
observed degeneration in the RPE and overlying receptors. Dry AMD can also progress 
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Table 1.1 The clinical age-related maculopathy (ARM) staging systems (Haddad et 
al” 2006;Tuo et al•，2004a) 
Grade of Clinical Features 
maculaopathy 
1 No drusen or < 10 small drusen without pigment abnormalities 
2 ^ 10 small drusen or < 15 intermediate drusen, or pigment 
abnormalities associated with ARM 
- Drusen 
- RPE changed (hyperpigmentation and hypopigmentation 
- Both drusen and RPE changes 
3 ^ 15 intermediate drusen or any large drusen 
- N o drusenoid retinal pigment epithelial detachment (RPED) 
- Drusenoid RPED 
4 Geographic atrophy (GA) with involvement of the macular center, 
or noncentral geographic atrophy at least 350|iim in size 
5 Exudative AMD, including nondrusenoid pigment epithelial 
detachments, serous or hemorrhagic retinal detachments, choroidal 
neovascular membrane (CNVM) with subretinal or sub-RPE 
hemorrhage or fibrosis, or scars consistent with treatment of AMD 
- S e r o u s RPED, without CNVM 
- CNVM or disciform scar 
Small = drusen < 63 jum in diameter located within 2 disc diameters (DDs) of the 
center of the macular; intermediate = drusen >63 jLim but < 125 jum，located within 2 
DDs of the center of the macula; large = drusen >125 in diameter located within 
2 DDs of the center of the macula. 
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Figure 1.4 Retinal fundus photos 
a) Normal retinal 
b) Dry AMD with characteristics drusen deposit (arrow) 
c and d) Wet/Exudative AMD with choroidal neovascularization 
(Picture is obtained and modified from online database, MD Support, Inc. & the 
National Low Vision Support Group. 
http://www.mdsupport.org/ anatomy.html) 
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to wet AMD, a second clinical form. While drusen are a risk factor to GA development, 
retinal pigmentary irregularities are a significant risk factor for the development of 
exudative AMD (Bressler et al., 1990). Earlier studies have reported about 90% of the 
cases to be dry AMD(Ferris, III et al., 1984). Recent studies have revised the prevalence 
to be about 80% and 20% to be the wet form (Allikmets et al., 1997). To date, no 
treatment for the atrophic form is available except for the use of antioxidants that delay 
the progression. 
1.3.2. Wet/Exudative AMD 
Wet AMD, also known as neovascular AMD or exudative AMD, is another advanced 
form of AMD that afflicts more severe visual loss than the dry AMD with atrophy. It is 
characterized by choroidal neovascularization (CNV) and/or RPE detachments. New 
vessels form under the retina, leading to the destruction of the serous RPE. Blood or 
fluid leaks from choroidal neovascular membrane, resulting in further scarring. This 
causes permanent damage to the surrounding retinal tissue, distorting and destroying 
central vision (Chang et al., 1999;Klein et al., 2006). Epidemiologic studies have shown 
that wet AMD is more prevalent among Asians than Caucasians, with most of the wet 
AMD advanced without drusen (Jonasson et al., 2003). Currently, there exists no 
treatment in AMD that can restore vision of the patient but to slower the progression of 
the disease. Laser photocoagulation and photodynamic therapy (PDT) are two laser 
treatments that help to stop further leakage temporarily by coagulating the vessel 
(Macular Photocoagulation Study Group 1994;Bonastre et al., 2002) . PDT has shown to 
prevent further visual loss and not to cure (Wormald et al., 2001). Anti-angiogenic drugs 
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have also been used to treat exudative AMD (Gillies et al.，2003). These treatments are 
of short-term effect and cannot restore visual impairment of the patients. Anti-vascular 
endothelial growth factor (anti-VEGF) agents, like ranibizumab and bevacizumab, have 
been shown to be effective in the treatment of neovascular/exudative AMD but their 
efficacy and potential risk need further investigation. 
1.4. Etiology and risk factors of AMD 
With the increase of life expectancy in the human population, the incidence of advanced 
AMD would be expected to be more prevalent. Identification of the etiology of AMD 
will be important for the early detection and prevention of the disease. There exists a 
growing spectrum of known AMD risk factors, whereby environmental, ethnic and 
genetic factors contribute most to its development, among which age is the most 
significant risk factor for the development of AMD. Gender, smoking and genetic factor 
also play a crucial role. 
1.4.1. Gender and Ethnicity 
Females, who have a longer life span, have a higher risk of advanced AMD (Smith et al., 
1997). Besides gender, population-based studies have shown ethnic differences in the 
prevalence of AMD. Drusen are more prevalent in both blacks and whites over age 40 
and elderly whites have more incidence of advanced AMD (Clemons et al., 
2005;Friedman et al., 1999;Klein et al., 1995). In epidemiological studies, Asians are 
found to have a higher incidence of exudative AMD than Caucasians (Bird, 2003;Chang 
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et al., 1999;Klein et al., 2006;Lim et al., 1998)，with the soft drusen found in dry AMD 
being rarely seen in them (Sandberg et al., 1998;Uyama et al., 2000;Yuzawa, 2000). The 
prevalence of geographic atrophy is found to be more in Iceland population (4.6% GA 
prevalence to none in exudative AMD) (Jonasson et al” 2003) and European population 
(80-85% of AMD cases) (Bonastre et al., 2002), whereas the exudative form of AMD is 
more prevalent in the Asian population (Chang et al., 1999;Klein et al., 2006;Lim et al., 
1998). The observed ethnic prevalence differences can be due to the underlying different 
genetic background and effects of different risk factors. 
1.4.2. Smoking and vascular factors 
Consistent population-based association studies have demonstrated that smoking is 
associated with higher risk of getting advanced AMD (Conley et al., 2006;DeAngelis et 
al” 2007;Fraser-Bell et al., 2006;0neill et al., 2001;Seddon et al l 1996;Smith et al., 
2001;Vingerling et al., 1996). The population attributable risk for AMD in former and 
current smokers has reported to be ranged from 20% to 68% (Mitchell P. et al., 1999). 
Smoking is hypothesized to alter the metabolism of the RPE by depressing the release of 
antioxidants and alteration of choroidal blood flow. The retina is thus subjected to 
oxidative stress due to its high consumption of oxygen. The free radicals and 
extracellular matrix along Bruch's membrane and the increased levels of the angiogenic 
factors in RPE cells from the insult of oxidative stress will then promote 
neovascularization (Mousa et al., 1999). Other risk factors like hypertension (Macular 
Photocoagulation Study Group 1997;Hyman and Neborsky, 2002), alcohol consumption 
(Fraser-Bell et al., 2006;Mitchell P. et al, 1999;Ritter et al., 1995), estrogen intake and 
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diet have been reported to show association to AMD risk but findings are being 
incoherent. 
1.4.3. Genetic Factor 
Substantial epidemiologic studies suggest that AMD has a significant genetic component 
involvement. Its complex nature, especially phenotypic heterogeneity, complicates the 
process of gene discovery. First-degree relatives of advanced AMD patients have shown 
a higher incidence and a relatively earlier age manifestation in familial aggregation 
analysis study (Klaver et al., 1998;Seddon et al.，1997). Earlier and recent twin studies 
reveal concordance of AMD manifestation in monozygotic than in dizygotic twin pairs, 
which further reinforce the importance of genetic factors in AMD risk (Hammond et al., 
2002;Meyers et al., 1995;Seddon et al., 2005). 
1.5. Molecular Genetics of AMD 
There have been advances in the analytical methods for complex genetic traits. However, 
the decipher of complex disorder by searching for susceptible loci and/or candidate 
genes has been less successful than that of simple Mendelian disorders like Huntington's 
disease and Cystic Fibrosis. There is no evidence for a Mendelian mode of inheritance of 
AMD, which is believed to be multiple traits with complex etiology. This is also 
probably due to complicating factors such as intervention of environment factors, 
incomplete penetrance of the disease, phenotypic and ethnic heterogeneity, polygenic 
effects and not to mention, the entity of late onset. 
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1.5.1. Linkage Studies 
Genome-wide linkage analysis is widely used over the past decades to map genetic 
susceptible loci to the disease phenotype. Linkage analyses search for regions in the 
genome with shared alleles among affected individuals within a family. This indicates 
that near to the proximity of this linked region there exists a disease-predisposing allele. 
About 500 polymorphic markers (microsatellite markers) across the genome will be 
adequate to detect the linked region. This gene mapping approach is powerful to identify 
rare high-risk disease alleles. 
Genome-wide linkage studies of AMD on large pedigrees, affected sib-pairs and 
discordant sib pairs have mapped a number of susceptible genetic loci lq, 2q, 3p, 6q, 9q, 
lOq, 16q 17q and 22q to AMD (Table 1.2) (Abecasis et al., 2004;Iyengar et al., 
2004;Kenealy et al., 2004;Majewski et al., 2003;Schick et al., 2003;Schmidt et al., 
2004;Seddon et al., 2003;Weeks et al., 2004;Weeks et al., 2001). Among these reported 
loci, consistent results are repeatedly obtained for lq31 and 10q26 by different research 
groups while the other loci have shown to associate with AMD risk with inconsistent 
findings. A recent genome-scan meta-analysis of six independent studies has further 
enriched the evidence of linkage on 10q26 and lq (Fisher et al” 2005). This meta-
analysis also shows weak evidence of linkage to chromosome 2p, 3p, 4q, 12q and 16q. 
Yet no significant disease-causing gene has successfully been identified with subsequent 
traditional positional cloning method. Following genome-wide scan, candidate genes 
screening on extended families and sib-pairs study was performed on exon 104 of 
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Table 1.2 AMD-related chromosomal loci identified by Linkage studies (Klein et al., 
1998) 
AMD Locus Marker Maximum LOD References 
lq25-31 D1S240/D1S412 3.20 (Weeks et al., 2001) 
(Majewski et al., 2003) 
(Seddon et al., 2003) 
(Iyengar et al., 2004) 
(Weeks et al” 2004) 
(Seddon et al., 2003) 
2q31/2q32 D2S1391/D2S1384 2.32/2.03 (Majewski et al., 2003) 
3pl3 D3S1300/D3S1763 2.19 (Schick et al., 2003) 
(Schick et al., 2003) 
6ql4 D6S1056/D6S249 3.59/3.17 (Majewski et al., 2003) 
9q33 D9S934/D9S934 2.06 (Majewski et al., 2003) 
10q26 D10S1230 3.06 (Kenealy et al., 2004) 
(Iyengar et al” 2004) 
(Weeks et al., 2004) 
(Jun et al., 2005) 
14q32.33 D14S1007 (Schmidt et al., 2004) 
16pl2 D16S403 2.9 (Weeks et al., 2001) 
17q25 D17S928 3.16 (Weeks et al., 2004) 
(Jun et al., 2005) 
19ql3.31 D19S245 (Seddon et al., 2003) 
22ql2 D22S1045 2.0 (Haddad et al, 2006) 
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Hemicentrin-1 and the 11 exons of EFEMP1 residing on lq31 and 2pl6, respectively, 
with no disease causing allele being identified (Iyengar et al.，2004). To date, genome-
wide linkage studies have identified associated susceptible loci that help to prioritize 
subsequent positional and functional candidate genes search. Difficulties to locate the 
genetic loci for AMD will be: 1) late disease-onset, 2) lack of big pedigrees, 3) 
variations in phenotype, 4) influences by environmental factors, and 5) heterogeneous 
and overlapping clinical features. 
1.5.2. Candidate genes search 
There is not much success in the course of positional cloning after the identification of 
susceptible loci from linkage studies. Table 1.3 summarizes candidate genes search with 
negative results (Haddad et al., 2006). In the locus lq25-31, being mapped from a large 
US pedigree (Schultz et al., 2003;Schultz et al., 2005;Weeks et al., 2001), one genetic 
variant, Gln5345Arg, in HEMICENTIN-1 located on lq25-31 is identified with 
segregation in the study family. Yet another group has reported no associated genetic 
variants with their AMD cases (Schultz et al, 2005;Stone et al., 2004). Table 1.4 
summarizes the candidate genes search with at least one positive association (Haddad et 
al., 2006). Most of the candidate genes searching for AMD have not been successful 
with mixed findings among different groups of study. The approach of candidate gene 
search is based on the analysis obtained from previous linkage studies and knowledge of 
the gene function. Inconsistent findings may be due to the genetic association being 
related solely to the studied family that might not exhibit the same genetic contribution 
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Table 1.3 Candidate Gene studies for AMD with negative results to date (modified 
from Haddad et al.，2006) 
Chromosome Gene References 
lq ADPRT1, EPHX1, GLRX2, (Conley et al , 2005; Esfandiary et 
LAMC1，LAMC2, LAMB3， al., 2005; Hayashi et al., 2004) 
PRELP, RGS19，TGFB2,OCLM 
2p EFEMP1 (Fibulin 3) (Guymer et al., 2002; Stone et al., 
1999) 
2q ILIA, Fibulin 2 (Haines et al., 2006; Stone et al., 
2004) 
3p GPX1 (Esfandiary et al., 2005) 
3q IMPG2 (Kuehn et al., 2001) 
6p RDS (Shastry and Trese, 1999) 
7 AhR (Esfandiary et al., 2005) 
8p NAT2 (Esfandiary et al., 2005) 
1 Oq CYP2E1 (Esfandiary et al., 2005) 
1 lp CAT (Esfandiary et al., 2005) 
1 lq Fibulin 4, VMD2 (Akimoto et al., 2001; Allikmets et 
al., 1999; Kramer et al., 2000; 
Seddon et al., 2001; Stone et al., 
2004) 
12p A2M, MGST1 (Haines et al., 2006) 
14q CKB (Haines et al., 2006) 
15q CYP1A1, CYP1A2 (Esfandiary et al, 2005) 
17q APOH, ITGB4 (Conley et al., 2005) 
22q CYP2D6, Fibulin 1，TIMP3 (De La Paz et al., 1997; Esfandiary 
et al., 2005; Stone et al” 2004) 
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Table 1.4 Candidate Gene studies for AMD with at least one positive findings to 
date (modified from Edwards et al., 2005) 
Chromosome Gene Reference 
lp ABCA4 (Allikmets, 2000; Allikmets et al., 1997; Baum 
et al., 2003; Bernstein et al., 2002; Fuse et al., 
2000; Guymer et al., 2001; Kuroiwa et al., 
1999; Rivera et al., 2000; Schmidt et al., 2003; 
Shroyer et al., 1999; Souied et al., 2000; 
Webster et al., 2001) 
lq HEMICENTIN (Abecasis et al., 2004; Conley et al., 2005; 
(Fibulin 6) Hayashi et al., 2004; Iyengar et al., 2004; 
Schultz et al., 2003; Stone et al., 2004) 
3p CX3CR1 (Tuo et al., 2004b) 
6p HLA Genes, VEGF (Churchill et al., 2006; Goverdhan et al., 2005; 
Haines et al” 2006) 
6q ELOVL4, SOD2 (Ayyagari et al., 2001; Conley et al., 2006; 
Esfandiary et al., 2005; Kimura et al., 2000) 
7q PON1 (Baird et al., 2004; Esfandiary et al., 2005; Ikeda 
et al., 2001) 
9p VLDLR (Conley et al., 2005； Haines et al., 2006) 
9q TLR4 (Zareparsi et al., 2005) 
12p LRP6 (Haines et al., 2006) 
14q Fibulin 5 (Stone et al., 2004) 
17q ACE (Conley et al., 2005; Haines et al., 2006; Hamdi 
et al., 2002; Hamdi and Kenney, 2003) 
19q APOE (Baird et al., 2006; Conley et al., 2005; Gotoh et 
al., 2004; Pang et al., 2000; Schmidt et al., 
2000; Simonelli et al., 2001; Souied et al., 
1998; Zareparsi et al., 2004) 
20p CST3 (Zurdel et al., 2002) 
20q MMP9 (Fiotti et al., 2005) 
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as in other studied families. Also, these observed genetic variants usually have mild 
genetic influence to the disease. 
Many investigators have proposed that inherited macular dystrophies, such as Best's, 
Stargadt's, Sorby's fundus, and peripherin/RDS related dystrophy, could be potential 
models for AMD. Various genes from some of these inherited macular diseases are 
chosen to perform further analysis on AMD patients since these monogenic macular and 
retinal diseases share similar clinical and pathological features with AMD. Contribution 
of these variants to overall AMD prevalence and development appears relatively 
insignificant since independent replication of the findings has been unsuccessful. 
Recently, follow-up on the identification of the AMD-susceptible locus on 10q26, 
subsequent analysis of the region by 93 SNPs for allelic association was performed by a 
group of researchers. With this different study approach, a hypothetical gene, 
LOC387715, as a susceptible gene to AMD risk was identified (Rivera et al., 2005). 
Recent findings from genome-wide association study have demonstrated Complement 
Factor H (CFH) conferring significant AMD risk, which will further be discussed in 
later section. Candidate gene approach given by the pre-knowledge of the complement 
system has led to the study of other genes in the system, factor B (BF) and complement 
component 2 (C2). These two genes are located in chromosome 6p and have been found 
to carry risk haplotypes and protective haplotypes to AMD (Gold et al., 2006). 
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1.5.3. Genome-Wide Association 
Linkage is known to map disease locations/loci. Association is to match the co-
occurrence of specific allele(s), genotype, haplotype at a specific locus/loci and the 
disease trait. The advent of HapMap project has identified many patterns of human 
genetic variation across the genome. This genetic variation, being the single nucleotide 
polymorphisms (SNPs), occurs ubiquitously across the genome in coding, non-coding 
and untranslated region. SNPs being much more common in the genome provide a 
higher resolution in genetic mapping. The common disease-common variant (CDCV) 
hypothesis predicts that common disease causing alleles will be found in populations. 
Complex polygenic diseases, which involve multiple genetic and environmental factors, 
are evolutionary neutral and are caused by these variations (Pritchard and Cox, 2002). 
Each variation in a complex disease will contribute a small effect on the disease 
phenotype resulting in additive or multiplicative effect of many susceptible alleles 
(Carlson et al., 2004;Collins et al., 1997;Yang et al., 2005). Susceptible variants 
involved in complex disease usually have low to medium penetrance. While linkage 
analysis approach is powerful to identify rare high-risk disease alleles, association 
analysis approach has better power to detect common disease arising from modest 
disease risk. The identification of inconsistent disease loci from linkage studies 
demonstrates its insufficient detection power and the difficulty in the study of the 
common disease with common variant hypothesis. Disease-predisposing variants are 
suggested to exist in the population at relatively high frequency. In order to identify 
genetic variants underlying complex disorders, very dense SNPs maps, providing 
adequate coverage of the human genome, must be used (Cardon and Palmer, 2003;North 
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et al., 2004). With the advancement of high throughput genotyping technique, this 
genome-wide association study approach has become more affordable. 
Association analysis is the speculation of the allele frequency of a set of polymorphic 
markers between cases and unrelated controls, with higher frequency in cases conferring 
a disease susceptible allele or a marker allele in linkage disequilibrium with the disease-
causing allele. 
1.5.3.1. Complement Factor H 
Recently, genome-wide association approach has identified a non-synonymous SNP 
encoding Y402H in complement factor H gene {CFH) on chromosome lq32 being 
significantly associated to the risk of dry AMD (Klein et al., 2005). This genetic 
variation is then replicated in other studies with similar significance level (Edwards et al” 
2005;Hageman et al., 2005;Haines et al., 2005). Consistent replications are also found in 
other ethnic population, French (ORhet=3.00; ORhom=6.93 to exudative AMD) (Souied et 
al., 2005), Dutch (C)R=11.02 to Stage 4 AMD) (Despriet et al., 2006), Italy (OR=3.9) 
(Simonelli et al., 2006), Russian (OR二2.71) (Fisher et al., 2006), Indian (OR =11.52; p-
value-1.19xl0"7) (Kaur et al., 2006)，German (ORhom=6.72) (Rivera et al., 2005) and 
Taiwan-Chinese (OR=4.4; p-value=10"6) (Lau et al., 2006). Table 1.5 summaries the 
findings on CFH Y402H prevalence on different ethnic populations. Divergent 
frequencies of CFH Y402H variant exist among different ethnic populations. In the 
Japanese population, a lower disease allele frequency of Y402H (MAF=0.04) than in the 
Caucasians (MAF=0.34) is observed that confer no association to exudative AMD (Fuse 
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Table 1.5 Odds ratio of CFH Y402H polymorphism conferring AMD in different 
ethnic populations 
E t h n i c AMD ORhom (Y402H) References 
Population 
Americans 395 (Dry or neovascular AMD) 4.54 (Klein et al., 2005) 
Americans 95 (Dry or neovascular AMD) 8.50 (Souied et al., 2005) 
French 141 (Neovascular AMD) 6.93 (Despriet et al , 2006) 
Netherlands 171 (GA and CNV) 11.02 (Simonelli et al., 2006) 
Italian 104 3.9 (Seitsonen et al., 2006) 
Finnish 154 (Dry and Exudative AMD) 9.33 (Rivera et al., 2005) 
German 1166 (GA and CNV) 6.72 (Fisher et al., 2006) 
Russian 151 (GA and CNV) 2.71 (Magnusson et al., 2006) 
Icelandic 581 (GA, Neovascular and Mixed 2.39 (Kaur et al., 2006) 
AMD) 
India 100 (Dry, GA and neovascular AMD) 11.52 (Lau et al., 2006) 
Taiwan- 163 (Neovascular AMD) 4.4 (Gotoh et al., 2006) 
Chinese 
Japanese 146 (Exudative AMD) ( MAF : 0.04 ) (Uka et al., 2006) 
80 (Dry AMD) (Fuse et al., 2006) 
(Matsuzaki et al., 2004) 
Chinese 163 (Exudative AMD) (MAF :0.04) (Chenet al., 2006) 
Abbreviations: ORhom, Odds Ratio of homozygous C allele 
GA, Geographic atrophy 
CNV, Choroidal neovascular AMD 
MAF, Minor allele frequency 
21 
et al” 2006;Gotoh et al” 2006;Uka et al., 2006). Low minor allele frequency (MAF=0.04) 
of Y402H is also observed in the Chinese population which harbors no association to 
exudative AMD subjects (Chen et al., 2006). In addition, they have also found other 
susceptible alleles in the promoter and coding regions of CFH and in different LD 
blocks to Y402H being associated to their exudative Chinese AMD subjects (Chen et al., 
2006). It has long been known that AMD prevalence varies differently in different 
ethnicities (Evans, 2001;Hsu et al” 2004;Klein et al” 2006;0shima et al., 2001;Varma et 
al” 2004) and so is phenotypic heterogeneity. This ethnic variation in AMD-associated 
CFH polymorphism suggests the possibility of other unidentified genetic factors 
important to the pathogenesis of AMD. These factors may act independently or to 
moderate the effects of the Y402H variant (Grassi et al” 2006). 
CFH is a regulator of the alternative pathway in the complement system. The 
complement system involves in the immune defense mechanism. The SNP at Y402H 
conferring risk to AMD is shown to have significant abnormal expression in the drusen 
(Mandal and Ayyagari, 2006). This genotype-driven abnormal regulation of the 
complement cascade within Bruch's membrane and adjacent retinal pigment epithelial 
cells result in uncontrolled complement activation and consequent drusen formation 
(Sivaprasad and Chong, 2006). 
1.5.3.2. LOC387715 
Association approach has also been used as a gene discovery screening tool to fine map 
on the susceptible disease loci being found in linkage studies. Numerous studies have 
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reported LOC387715 as a second major locus related to the pathogenesis of AMD. 
LOC387715 is a hypothetical gene residing on 10q26. A non-synonymous coding SNP, 
A69S, in LOC387715 confers a significant association to AMD risk with 7.6-fold 
increased risk in homozygote carrier (Rivera et al., 2005). These findings are replicated 
in an independent case control cohort (Francis et al., 2007). CFH Y402H variants also 
exhibit strong association to this study cohort. These results suggest an independent 
contribution effect of CFH and LOC387715 on AMD risk. Other groups also replicate 
the same findings with LOC387715 conferring significant risk to AMD (Conley et al., 
2006;Jakobsdottir et al., 2005;Schmidt et al., 2006;Shastry, 2006). 
1.6. Statistical Analysis 
1.6.1. Genotyping 
Microarrays have been widely used for gene expression study and genomic variation 
study. For genomic variation study, Comparative Genome Hybridization (CGH) array 
and SNP-based array are the two common types. SNPs occur one in every 300 to 1000 
base pairs throughout the genome. In genomic research, SNP microarrays are used in the 
attempt to identify DNA sequence variants in specific genes or regions of the human 
genome that are responsible for a variety of phenotypic traits, such as disease risk or 
variable drug response. The Affymetrix genotyping platforms provide thousands of 
SNPs from the human genome on a single chip. With the advances in photolithography-
based array technology, feature sizes are reduced from 18jnm down to 8|xm, which 
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increase the density five-fold to � 2 . 5 million unique probe sequences per array. The 
GeneChip® Human Mapping 100K array (Affymetrix Inc, Santa Clara, California, USA) 
is available on two chips. Recently, the 100K SNP set has been successfully utilized in 
the search of a highly significant susceptible disease allele, CFH Y402H, to the risk of 
dry AMD with the presence of large drusen (Klein et al., 2005). The genome coverage 
of the 100,000 SNPs is shown in Table 1.6. The highly dense genome coverage of this 
SNP chip will be of high opportunity to identify genomic variants associated with the 
disease studied. 
The SNP arrays contain probe sets to interrogate the two alleles for all the SNPs. 25-mer 
oligonucleotide probes corresponding to a perfect match for the allele sequence and to a 
perfect match for the other allele sequence. In addition, a mismatch probe is synthesized 
for each allele to detect non-specific binding. This quartet probe is the basic unit for 
detecting different genotype groups: AA, AB or BB. A new dynamic model-based 
algorithm DM for the Mapping 100K array is used to call the genotype. 
1.6.2. Quality Assessment of Genetic Data 
Analysis of genotyping data created from association study is complex. Firstly, Hardy-
Weinberg equilibrium must be tested for each control genotype. Its violation indicates 
existence of population stratification in the study, systematic errors in genotyping, 
random chance, or presence of homologous region in the genome (Cardon and Palmer, 
2003). Those genotyping data should be critically examined to scrutinize any genotyping 
errors and the impact from HWE violations (Trikalinos et al., 2006). Markers with 
violation of Hardy-Weinberg equilibrium should be excluded in the subsequent analysis. 
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Table 1.6 Genome coverage Affymetrix GeneChip® Human Mapping array 
(Nicolae et al” 2006) 
Genotyping over 100,000 SNPs 
Genome coverage 
Range All SNPs Hind SNPs Xba SNPs 
±2000 bp 11.4% ^8% 0 % 
士 5000 bp 24.4% 13.3% 13.7% 
± 10000 bp 40.5% 23.9% 24.6% 
士 20000 bp 59.9% 39.9% 41.1% 
±50000 bp 81.9% 66.2% 67.5% 
± 100000 bp 91.6% 82.7% 83.9% 
± 500000 bp 98.8% 98.0% 98.2% 
± 1000000 bp 99.1% 98.9% 99.1% 
±5000000 bp 99.1% 99.1% 99.1% 
Genome Coverage: 
Total genome size was 3.069 Gbases of which Gaps (centromeres, telomeres, and 
heterochromatin) accounted for 0.226 Gbases, leaving an effective genome size of 
2.843 Gbases. Chromosome size and Gap information for genome Build 34 was 
downloaded from the UCSC Genome Browser (http://genome.ucsc.edu/cgi-
bin/hgText). For each chromosome, non-overlapping ranges about each SNP site 
were summed, and then divided by the effective size of the chromosome to 
estimate genome coverage. Chr—random chromosomes were omitted. 
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1.6.3. Association Analysis 
Each marker is analyzed individually for association to the disease. Chi-square test with 
one degree of freedom is performed to test for association. If expected cell counts are 
small (<5), Fisher's exact test is preferred (Clayton and McKeigue, 2001). Odds ratio 
(OR) is widely used as a relative measure of association. The OR for disease is the ratio 
of allele carriers to non-carriers in cases compared with that in controls. It indicates the 
increase in disease risk for carriers comparing to non-carriers. In the study, the less 
frequent allele in the control group was considered to be the risk allele. 
1.6.4. Population Stratification 
Population structure is a factor to be addressed for spurious association observed. 
Population stratification refers to differences in allele frequencies between cases and 
controls due to systemic differences in ancestry rather than association of genes with 
disease. This difference will contribute to spurious association. This confounding of 
subpopulations will need to be tested and corrected before performing any further 
association analysis. Genomic control is one of the methods for this correction. It treats 
the population ancestry as a nuisance parameter within the modeling, and removes the 
effect from the association test statistic for correction (Devlin and Roeder, 1999). 
1.6.5. Haplotype Analysis of Multiple SNPs 
Substantial evidence has accumulated that the genome can be divided into haplotype 
blocks of variable lengths (Daly et al” 2001;Gabriel et al” 2002). Within these blocks, 
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LD is strong, that is, the alleles at different loci are not randomly assorted but allelic 
states are highly correlated. While between blocks, LD is disrupted, presumably due to 
historical recombination. Closely linked alleles within the haplotype block tend to be 
inherited together. If a haplotype contains the disease allele, the subsequent 
recombination events will carry the disease allele along. Haplotype analysis will help to 
determine if there exists an increase risk of developing disease. It is mentioned to 
provide a greater power to detect association than single SNP analysis (Clayton and 
McKeigue, 2001;Johnson et al., 2001). 
Haploview (Barrett et al” 2005) is designed as a tool to analyze, interpret, visualize and 
depict haplotype block structure using accelerated E-M algorithm. Haplotype block can 
help to identify closely linked alleles that are in linkage disequilibrium, which can then 
be employed to identify genetic regions associated with disease. Gold is another 
software that provides a graphical summary of linkage disequilibrium in human genetic 
data (Abecasis and Cookson, 2000). 
1.6.6. Population Attributable Risk 
Population attributable risk (PAR) estimates the proportion of disease in the study 
population that is attributable to the exposure. A general formula for the calculation of 
the PAR is (Bruzzi et al., 1985): 
PAR = Pr(OR - 1)/ (1 + Pr (OR- 1)) 
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，where P ris the prevalence of the risk factor in the general population. 
This is the measure of the effects of exposures. 
1.6.7. Interaction Analysis 
Most common diseases arise from interaction between multiple genetic variations and 
factors such as environment. The interaction between genetic polymorphisms is referred 
to as epistasis, which means that the effect of one locus varies according to the genotype 
present at another locus. It has been stated that epistasis accounts for a situation where a 
‘masking, gene prevented another phenotypic gene from exhibiting its effects (Cordell, 
2002). Logistic regression with modeling of joint loci effect is one approach to study 
interaction effect of two loci on disease phenotype (Cordell, 2002). Models are fitted 
into the additive effect and dominance effect of each disease locus and the between-loci 
additive and dominance interactions. The effects of four alleles present at two loci are 
partitioned into main effects and various interaction terms. The multiplicative model 
represents epistasis (Risch, 1990). Epidemiologically, AMD is a complex disorder with 
contributions of both environmental and genetic risk factors. Smoking is known as one 
of the most important risk factors of AMD ( Seddon et al” 2006a; Seddon et al., 2006b). 
Recent association study has identified CFH as a major AMD-predisposing gene (Klein 
et al., 2005). The investigation of gene-environment and gene-gene interaction will help 
to further understand the pathogenesis of AMD. 
1.7. Objectives 
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Linkage studies have repeatedly mapped AMD to two chromosomal loci, lq32 and 
10q26. The Y402H variant of the CFH gene on chromosome lq32 has been shown to be 
a major risk factor to dry type of AMD, especially with presence of large drusen. We 
have recently shown that sequence variants of CFH, including rs3753394 (p二0.003)， 
rs800292 (p二0.00053)，and rsl329428 (0.00092), but not rsl061170 (Y402H), have 
significant associations with exudative AMD in the Chinese population. Our data have 
shown both ethnic constitutional differences and probable inductive differences in the 
molecular genetics of AMD that may affect their phenotypic expressions, and 
consequently cast important influences on the modes of treatment. In the work described 
in this thesis, we confined to Chinese exudative AMD patients and focus on the putative 
AMD locus on chromosome 10q26: 
1. to search for the associated gene of AMD, 
2. to identify the gene variants that cause or predispose to development of AMD, and 
3. to examine gene-environment and gene-gene interaction effects. 
We utilized genome-wide linkage disequilibrium association, positional cloning and 
direct sequencing in this study. 
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Chapter 2 
Materials and Method 
2.1. Materials 
2.1.1. Proteins 
All restriction endonucleases and T4 DNA Ligase were purchased from New England 
Biolabs, MA, USA. ExoSap-IT was obtained from GE HealthCare Bio-Sciences, Little 
Chalfont, United Kingdom. Proteinase K was purchased from QIAGEN Gmb, Hilden, 
Germany. Platinum Taq polymerase, Platinum Pfx DNA polymerase and Human Cot-1 
were obtained from Invitrogen Corporation, Carlsbad, CA, USA. Anti-streptavidin (goat) 
biotinylated antibody was purchased from Vector Laboratories, USA. 
2.1.2. Chemicals 
Gene Page Plus 5.25% 6M urea and N,N,N',N'-tetramethyl ethylenediamine (TEMED) 
was purchased from AMERESCO, Solon, OH, USA. Agarose, ammonium acetate, 
ammonium persulfate (APS), P-mercaptoethanol, boric acid, bromophenol blue, 
denhardt's solution, dextran, dimethylsulfoxide (DMSO), ethylenediaminetetraacetic 
acid (EDTA) di-sodium salt dihydrate，ethanol (absolute), ethidium bromide, glycerol, 
isopropanol, methanol, potassium chloride, potassium dihydrogen phosphate, sodium 
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bicarbonate, sodium chloride, sodium dihydrogen phosphate, tris base，Tween-20 and 
xylene cyanol FF were obtained from Sigma-Aldrich Co., St. Louis, MO, USA. 50X 
TAE and lOx TBE were purchased from Bio-Rad Laboratories, Hercules, CA，USA. 
dNTP set was obtained from Roche Diagnostics GmbH, Penzberg, Germany. Adaptor 
Xba and adaptor Hind were product of Affymetrix Inc, Santa Clara, USA. 
2.1.3. Solutions and Buffers 
Loading Buffer, 6X 0.25% bromophenol blue, 0.25% xylene cyanol 
FF and 30% glycerol 
RLT buffer, working stock RLT buffer with 10|il/ml P-mercaptoethanol 
TAE buffer, 50X 2M Tris-Acetate, 50mM EDTA, pH8.3 
TBE buffer, 10X 1.0M Tris, 0.9M Boric acid, lOmM EDTA, 
pH8.4 
SSPE buffer, 20X 3M sodium chloride, 0.2M sodium dihydrogen 
phosphate, 0.02M EDTA 
2.1.4. Reagents and kits 
Affymetrix GeneChip® Human Mapping 100K Set of microarrays and GeneChip 
Mapping Assay were purchased from Affymetrix Inc, Santa Clara, USA. QIAamp DNA 
Blood Midi kit was obtained from Qiagen, Hilden, Germany. BigDye Terminator Cycle 
Sequencing Reaction Kit v3.1 was purchased from Applied Biosystems, Foster City, CA, 
USA. Fifty base pair and 1 kilo base DNA ladder and custom primers for sequencing 
and PCR were obtained from Invitrogen Corporation, Carlsbad, CA, USA. 
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2.1.5. Apparatus 
GeneChip Scanner 3000 and Fluidics Station were obtained from Affymetrix Inc, Santa 
Clara，USA. ABI 3130XL automated DNA sequencer and GeneAmp PCR System 9700 
were purchased from Applied Biosystems, Foster City, CA, USA. All plastic wares were 
obtained from Labcon Inc., CA, USA. Gel-Doc 2000 video gel documentation system 
was purchased from Bio-Rad Laboratories, Hercules, CA, USA. Nanodrop ND-1000 
was purchased from NanoDrop Technologies, Rockland, DE，USA. Mupid-2 Mini-Gel 
Electrophoresis System was obtained from Cosmo Bio Co. Ltd., Tokyo, Japan. 
2.1.6. Softwares 
GeneChip Operating software (GCOS) and GeneChip DNA Analysis Software (GDAS) 
was obtained from Affymetrix Inc, Santa Clara, USA. ABI Prism 3130XL Sequence 
Collection and SeqScape were purchased from Applied Biosystems, Foster City, CA, 
USA. Quantity One® Version 4.0.3 Image Analysis System was obtained from Bio-Rad 
Laboratories, Hercules, CA, USA. Statistical Packages for Social Science (SPSS) 
version 11.3 was purchased from SPSS, Chicago, IL. R language and environment for 
statistical computing version 1.4.0 was downloaded from The R project for Statistical 
Computing Homepage (http://www.R-proiect.org). 
2.2. Methods 
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2.2.1. Study Subjects 
The study protocol was approved by the Ethnics Committee for Human Research of the 
Chinese University of Hong Kong. All the procedures used in the study conformed to 
the tenets of the Declaration of Helsinki. Informed consent was obtained from all study 
subjects after explanation of the nature and possible consequences of the study. Detailed 
family and medical histories were documented. Peripheral venous blood was taken from 
each subject for genetic studies. 
2.2.2. AMD Patients 
All participants received a standard examination protocol and visual-acuity measurement. 
All subjects underwent a detailed eye examination, including best corrected visual acuity 
and slit lamp biomicroscopy of the fundi. Stereoscopic color fundus photographs were 
taken using the standard classification suggested by the International Age-related 
Maculopathy Epidemiological Study Group. Patients with exudative AMD had 
nondrusenoid RPED (retinal pigment epithelium detachment), CNV (chroidal 
neovascularization), serous or hemorrhagic retinal detachments, subretinal or sub-RPE 
hemorrhage or fibrosis. In addition, smoking habits were recorded. A smoker is defined 
as a person who smoked at least 5 cigarettes daily for more than 1 year. Smokers were 
divided into two groups: those who had never smoked, and those who were ex-smokers 
and current smokers. A total of 164 exudative AMD were recruited with 88 males and 
75 females. The age at diagnosis ranged from 60-94 years, mean 75.5 士 7.5 years. For 
the genome-wide association study, those cases over 90 years of age were excluded to 
closely match the age distribution between cases and controls. A final of 96 
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cases were used in the study. Follow-up on the candidate gene screening, all of the 164 
exudative AMD were analyzed in the study. 
2.2.3. Control Subjects 
The control subjects did not have family history of AMD or showed no sign of AMD or 
any other major eye diseases except senile cataracts. Fundus examination was normal for 
the control subjects. A total of 183 controls were recruited and used in the candidate 
gene screening study, among which 130 were used in the genome-wide association study 
since those control subjects younger than 65 years of age were excluded. The 
characteristics of the final group of 96 cases and 130 controls are given in Table 2.1. 
2.2.4. DNA Extraction and Quantification 
Genomic DNA was extracted from EDTA-blood using Qiagen QIAamp DNA Blood 
Midi kit (Qiagen, Hilden, Germany) according to the manufacturer's Blood and Body 
Fluid Spin Protocol. The final genomic DNA was eluted with 400jnl sterile milli-q water. 
The extracted DNA was quantified by UV-Visible spectrophotometer, Nanodrop ND-
1000 (NanoDrop Technologies, Rockland, DE, USA). 
2.2.5. Whole genome wide SNP scanning 
Each cases and control subjects were genotyped using the Affymetrix GeneChip® 
Human Mapping 100K Set of microarrays (Affymetrix Inc, Santa Clara, USA). The SNP 
genotyping assay consisted of two chips (Xbal and Hindlll) with 58,960 and 57,244 
SNPs, respectively. Approximately 250ng of genomic DNA was digested with two 
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Table 2.1 Characteristics of cases and controls in the genome-wide association 
study 
Exudative AMD Controls 
Total 96 130 
Males (%) 68 33 
Mean Age (±s.d.) (years) 74.9 土 6.8 74.2 士 5.7 
Age range (years) 69 - 89 65 - 99 
Smokers 63 26 
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restriction enzymes Xbal and Hindlll (New England BioLabs Inc, MA, USA), followed 
by GeneChip Mapping Assay (Affymetrix Inc, Santa Clara, USA) according to the 
manufacturer's protocol. Figure 2.1 shows the flowchart of the procedure. The images 
were scanned on GeneChip Scanner 3000 (Affymetrix Inc, Santa Clara, USA) and 
analyzed using GeneChip DNA Analysis Software (GDAS) (Affymetrix Inc, Santa 
Clara, USA). For each chip, two internal control measures were used: the call rate 
always exceeded 90% and heterozygosity on the X chromosome correctly identified the 
gender of the individual. To ensure that no samples were confused, identical SNPS 
placed on both chips were checked for yielding the same genotype for the same 
individual. 
Three experiments were done to assure reproducibility of the system. First, four samples 
were processed twice with the Xba chips. Next, two replicates of a reference DNA 
positive control provided by Affymetrix were run on Xba chips alongside the samples 
described here. Finally, results for three individuals were compared with genotyping 
using the Affymetrix 10K SNP platform for accuracy test. These hybridization 
experiments were performed in Dr J Hoh's laboratory of Yale University. 
Those individual chips achieving a call rate of >90% were used for the analysis. One 
Xbal chip was eliminated due to an extremely low call rate (76.72%). This sample was 
not genotyped on the Hindlll chip. One individual was not successfully genotyped on 
either chip, and three others only when using the Hindlll chip. This left with 268 
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Figure 2.1 Flow chart of the Genotyping procedure of the Affymetrix GeneChip® 
Human Mapping set (www.affymetrix.com) 
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individuals genotyped for Hindlll and 266 for Xbal (266 of which were genotyped for 
both chips). 
After eliminating this one chip, individual autosomal SNP data quality was assessed by 
examining the call rates. SNPs with call rate <85% were eliminated from the analysis. 
To further eliminate SNP with possible genotyping errors, heterozygous SNPs without 
observed heterozygotes and SNPs with only heterozygotes were excluded. To eliminate 
uninformative SNPs, non-heterozygous SNPs were excluded. Finally, deviations from 
Hardy-Weinberg equilibrium (HWE) were assessed, and SNPs with a HWE ^>50 were 
excluded. These exclusions were largely due to low call rates of <85%; hence, 97,824 
autosomal SNPs were left for analysis. These data are summarized in Table 2.2. 
2.2.6. HTRA1 Genotyping 
With the susceptible SNP to risk of exudative AMD identified as rsl0490924, the 
HTRA1 gene, lying next to it and in LD with it was chosen for candidate gene screening. 
The cases and controls were selected with the same criteria as in the genome-wide 
association study. A final of 163 exudative AMD and 183 control subjects were chosen 
for the analysis. 
2.2.6.1. Serial Polymerase Chain Reaction 
PCR reactions were carried out in a total volume of 25 jul containing 20 mM Tris-HCl 
(pH8.4), 50 mM potassium chloride (KC1)，1.5mM magnesium chloride (MgCl2)，0.5 
juM of each amplicon specific primer, 0.2 |nM deoxynucleotide triphosphate (dNTP) mix, 
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Table 2.2 Genotyping data quality 
Number of Individuals 
Hind 268 
Xba 267 
Pre-chip data quality 
Median call rate per chip (Hind) 99.41% 
Median call rate per chip (Xba) 99.33% 
Minimum call rate per chip (Hind) 94.33% 
Minimum call rate per chip (Xba) 76.72%* 
Per-individual data quality 
Average number of matches for common SNP between two chips# 30.7 
Minimum number of matches for common SNP between two chips# 26 
Total Number of SNPs 116204 
Number of Autosomal SNPs 113 841 
Call rate (per SNP) 
SNPs with 100% call rate 71156 
SNPs with call rate between 85% and 100% 41934 
SNPs with call rate less than 85% 751 
SNPs with call rate above 85% (Hind; 40 or less No Calls) 113090 
Locus Polymorphism (for autosomal SNPs with call rates > 85%) 
Number of SNPs with no polymorphism observed 14867 
Number of SNPs with only heterozygotes observed 17 
Number of polymorphic SNPs with no heterozygotes observed 36 
Number of SNPs with minor allele frequency <0.01 6008 
Hardy-Weinberg Equilibrium (for polymorphic SNPs regardless ofMAF) 
Number of SNPs with HWE ^2 > 50 346 
Final number of SNPs 97824 
* After the one Xba chip with low call rate was removed, there were 266 samples genotyped on 
the Xba chip and the minimum call rate was 95.85%. 
#Out of the 31 SNPs that are in common between the two chips. 
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1 unit of recombinant Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, 
CA，USA) and 200ng template DNA. The PCR temperature profile consisted of 
denaturation of the DNA at 94°C for 5 minutes, cycling 40 cycles at 94°C for 40 seconds, 
an amplicon specific annealing temperature for 50 seconds and 72°C for 40 seconds. 
This was followed by a 7-minute extension step at 72°C. All primer sequences and 
amplicon specific annealing temperature are listed in Table 2.3. 
2.2.6.2. Cycle Sequencing 
lOjil of PCR products were treated with 2|nl ExoSap-IT (GE HealthCare, USA) and 
incubated at 37°C for 30 minutes to remove excessive primers and dephosphorylate 
excessive dNTPs before cycle sequencing. The enzymes were then inactivated at 72°C 
for 15 minutes. The purified DNA products were subjected to cycle sequencing using 
BigDye Terminator Cycle Sequencing Reaction Kit (v3.1, Applied Biosystems, Foster 
City, CA, USA) according to manufacturer's protocol on ABI 3130XL capillary DNA 
sequencer (Applied Biosystems, Foster City, CA, USA). Sequencing data were aligned 
by SeqScape (Applied Biosystems, Foster City, CA, USA) and analyzed accordingly. 
The data were compared with the reference sequence, ENSG00000166033, from 
Ensembl webpage. 
2.3. Statistical Analysis 












































































































































































































































































































































































































































































































































































































































































Hardy-Weinberg equilibrium for all SNPs and sequence variants were tested to eliminate 
any genotyping error by Chi-square test. The SPSS statistical software was used (SPSS 
verll.3; SPSS Inc., Chicago, IL, USA). 
2.3.2. Association Analysis: Linakge disequilibrium 
For genome-wide association study, the initial analysis was carried out by constructing 2 
x 2 tables of the allele counts and 2 x 3 tables of the genotype counts for each SNP in all 
cases and controls. Subsequently, Pearson's Chi-square statistics were calculated and p-
values computed by comparing the ^ statistics to a x2 distribution with 1 or 2 df for the 
allelic and genotypic tests, respectively. SNPs yielding a p-value smaller than 2 x 10"7 
(Bonferroni adjusted significance of 0.05 [0.05/97,824x2]) were selected for further 
analysis in the genome-wide association study. In order to avoid spurious associations in 
genome-wide association study rigorous statistical thresholds are applied. Although 
bonferroni correction of multiple testing is a conservative approach, smaller p-values 
generally provide greater support for a true association. Odds ratios, its respective 
confidence intervals and population attributable risks were calculated accordingly. 
Similar statistical approach was applied in the candidate gene screening study. In the 
candidate gene screening study, the less frequent allele in the control group was 
considered to be the risk allele. Chi-square test or Fisher's exact test was used in the 
association analysis to compare the frequencies of various alleles or genotypes between 
the cases and controls. The OR was calculated by comparing those homozygous for the 
risk allele (RR) to the baseline group (those homozygous for the normal allele, NN) 
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(ORhom) and comparing those heterozygous for the risk allele (RN) to the baseline group 
(ORhet). The contrasts for dominant (RR and RN versus NN) and recessive (RR versus 
RN and NN) effects were also evaluated. Bonferroni method was used for the correction 
of multiple testing. The SPSS statistical software was used for the calculation (SPSS 
verll.5; SPSS Inc., Chicago, IL, USA). 
2.3.3. Haplotype Analysis 
The SNPHAP (David Clayton's Web site) and the PHASE (Stephens et al., 2001) 
algorithms were used to construct haplotypes around the region of interesting SNP(s). 
The Haploxt program (Gonqalo Abecasis' Web site) was used to calculate the D\ a 
standard measure of LD. LD combined case/control samples were then visualized using 
GOLD (Abecasis and Cookson, 2000). Estimated haplotype frequencies for the case and 
control groups combined and for each separate group would be calculated. The most 
probable haplotype pair for each individual was obtained in PHASE (Stephens et al., 
2001) and then used to create contingency table and to estimate the effect size of the risk 
haplotype. 
For candidate gene screening, pairwise SNP LD coefficient D' were calculated by 
Haploview (Barrett et al., 2005). In addition, subsequent haplotype counts between cases 
and controls were compared and analyzed accordingly. 
2.3.4. Interaction Analysis 
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Gene-environment and gene-gene interaction analysis for AMD were conducted using 
smoking and CFH gene, respectively. Only subjects with smoking status were analyzed 
which left 143 exudative AMD and 153 controls in the gene-environment interaction 
analysis. Smoking was coded as “0” for never-smokers and “1” for ever-smokers. The 
interaction effect of smoking and HTRA1 was analyzed in a similar fashion as mentioned 
below. 
Six CFH SNPs were assessed for their susceptibility with exudative AMD in a previous 
published study (Chen et al” 2006). In this study, no association of Y402H at CFH was 
found to be associated with exudative AMD. Yet another SNP, rs800292, was identified 
to be significantly associated with AMD. Hence, this SNP at CFH together with the 
significant SNP at HTRA1 were evaluated for their interaction effect on exudative AMD. 
Their joint contribution to AMD predisposition was assessed by logistic regression 
analysis implemented in R (R statistical analysis package: http://www.r-project.org/), 
modeling case-control status on CFH and HTRA1 genotypes. A series of models were 
fitted in order to draw inferences about the most likely and most parsimonious model(s). 
Both additive (coded 0，1 and 2 for the number of copies of haplotype) and dominance 
(coded 1 for possessing exactly one copy of a haplotype and 0 otherwise) effects of each 
haplotype were considered in the modeling. Models allowing for additive effects (ADD1， 
ADD2 and ADD1+ADD2), and models incorporate dominance effects (DOM1, DOM2 
and DOM1+DOM2) were also fitted. The ADD1 model includes only the additive 
effects of HTRA1 at rsl 1200638 whereas the ADD2 model includes only the additive 
effects of CFH at rs800292. The ADD1+ADD2 models the joint additive effects of 
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HTRA1 and CFH. The D0M1 incorporates dominance effects to ADD1 at rsl 1200638 
oiHTRAl and the DOM2 model similarly incorporates dominance effects to ADD2 at 
rs800292 of CFH. DOM1+DOM2 models the joint dominance effects of HTRA1 and 
CFH. Three further interaction models are fitted between HTRA1 and CFH. 
ADD1*ADD2-INT includes the interactive effects of additive model of HTRA1 and 
CFH. ADD*DOM-INT includes the interactive effects of additive model oiHTRAl and 
CFH, additive model of HTRA1 and dominance model of CFH, and dominance model of 
HTRA1 and additive model of CFH. ALL-INT includes all the interactive effects 
mentioned and the interactive effect of dominance model of HTRA1 and dominance 
model of CFH. Models were compared using the Akaike information criterion (AIC) 
(North et al., 2005). The best fit model will give the smallest AIC. Models were 
considered to be statistically indistinguishable when AIC differed being <2 units; and 
the model having fewer parameters was chosen as the best fit and most parsimonious 
model. The joint ORs of the risk factors were further estimated in this most best fitted 
and parsimonious model. The baseline haplotype is the observed individuals with the 




3.1. Genome-wide Association Study of Exudative AMD 
3.1.1. Genotyping and Association Analysis 
rs10490924 was the only polymorphism that showed a significant association with AMD 
using Bonferroni criteria (Table 3.1) out of the 97,824 autosomal SNPs that were 
informative and passed the quality control checks. The allele frequency x2 test yielded a 
p-value of 4.1 x 10'12 (Figure 3.1A and Table 3.1). The OR was 11.1 (95% confidence 
interval [CI] 4.83-25.69) for those carrying two copies of the risk allele when compared 
to wild-type homozygous, but with indistinguishable from unity 1.7 (95% CI 0.75-3.68), 
for those having a single risk. The risk homozygote accounted for 86% of the population 
attributable risk (PAR), although this number may be artificial inflated since the risk 
allele was carried by more than half (-55%) of the AMD cohort (Table 3.1). When 
likelihood ratio tests were adjusted for gender and smoking status or when genomic 
control for population stratification, there was little change in significance levels. 
SNPS rs 10490924 is situated in a hypothetical gene, LOC387715, and resides between 
two genes on chromosomes 10q26 (Figure 3. IB): PLEKHA1 encoding a pleckstrin 
homology domain-containing protein (GenBank ID59338) and HTRA1 encoding a heat 
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Figure 3.1 Genome-wide distribution of p-values and characteristics of the 
associated genome region. 
(A) Distribution of p-values for the SNPs in a whole-genome association 
study of AMD. P-values are plotted as the loglO(P) with the SNPs in 
chromosome order along the x-axis. The dashed horizontal line indicates 
the Bonferroni adjusted threshold for significant association at the 0.05 
level. 
(B) A schematic of the genes in the 4-gamete region on chromosome 
10q26, as well as the location of SNPs genotyped by microarrays (+) 
and identified through sequencing ( | ). SNP rsl0490924 is labeled as 
“8” and rsl 1200638 is marked with an asterisk. Above is the gene 
conservation data obtained from the University of California Santa Cruz 
(UCSC) Golden Path database for the 4-gamete region. The data show 
the degree of evolutionary conservation among 17 species using the 
multiz alignment; an increase in the height of the bar indicated an 
increase in the level of conservation. 
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shock serine protease also known as PRSS11 (GenBank ID 5654). The low sequence 
homology across species in the intergenic region containing rs 10490924 indicates that it 
is not evolutionarily conserved (Figure 3.IB). 
3.1.2. Haplotype Analysis 
The region bounded by pairwise SNPs, in which four gametes were observed, was 
examined to identify the region of interest around rs 10490924. This region was being 
referred to the "4-gamete region，，. The pattern of linkage disequilibrium (LD) was 
examined by constructing haplotypes for the seven internal SNPs in the region using 
SNPHAP (David Clayton's Web site) and the PHASE (Stephens et al., 2001) algorithms. 
Both algorithms yielded the same haplotypes with similar frequencies. With the 
construct of haplotypes, the Haploxt program (Gon^alo Abecasis' Web site) was used to 
calculate the D’，a standard measure of LD. LD combined case/control sample were then 
visualized using GOLD (Abecasis and Cookson, 2000) and was illustrated in Figure 3.2. 
Estimated haplotype frequencies for the case and control groups combined and for each 
separate group were given in Table 3.2. The most probable haplotype pair for each 
individual was obtained from PHASE (Stephens et al” 2001) and then used to determine 
haplotype counts given in Table 3.3. These haplotype counts were used to create the 
contingency table and to estimate the effect size of the risk haplotype given in Table 3.4. 
To investigate the pattern of LD in this region, the publicly available HapMap database 
was utilized, which contains information on 45 unrelated Han Chinese individuals from 
Beijing (CHB). Genotypes for 183 SNPs bound by the 4-gamete region were extracted 
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Figure 3.2 Linkage disequilibrium (LD) plot in GOLD of the D，values for the nine 
SNPs that define the 4 gamete region surrounding rsl0490924. Red 
indicates a £>，value of 1.0 and Blue indicates a value of 0.0. The marker 
map is as follows 1 = rsl0510109, 2 = rs2421019, 3 = rs2292623, 4 二 
rs2292625, 5= rsl0510110，6 = rs2280141, 7 二 rs2736911, 8 二 rsl0490924， 
9 = rs2284666. Notice that the edge of the region of high LD ends at 
rsl0490924. The seven markers used for the haplotype construction were 
2 - 8 . 
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Table 3.2 Haplotype analysis of seven SNPs: rs2421019, rs2292623, rs2292625, 
rsl0510110, rs2282141, rs2736911, rsl0790924 in the 4 gamete region. 
Haplotype frequency estimates as determined by PHASE for the entire 
population "all" and for the case and control populations separately. 
T/C A/G A/G T/C T/G T/C T/G ALL Case Control 
N 1 2 1 2 2 2 2 1 0.45743 0.61100 0.34024 
N 2 2 1 2 2 2 2 2 0.17255 0.09849 0.22908 
N 3 2 2 2 1 1 1 2 0.14944 0.12047 0.17154 
N 4 1 1 2 1 1 2 2 0.07105 0.03783 0.09640 
N 5 1 1 2 1 1 2 1 0.05739 0.05845 0.05659 
N 6 1 1 1 1 1 2 2 0.03777 0.03009 0.04363 
N 7 2 2 2 1 1 2 1 0.02841 0.02597 0.03026 
N 8 2 2 2 1 1 2 2 0.01989 0.01302 0.02514 
N 9 2 1 2 2 2 1 2 0.00364 0.00021 0.00626 
N 1 ° 2 2 2 2 2 2 1 0.00188 0.00431 0.00003 
N 1 1 1 1 2 1 1 1 2 0.00041 0.00004 0.00068 
N 1 2 1 1 1 1 1 2 1 0.00006 0.00006 0.00006 
N 1 3 2 1 1 2 2 2 2 0.00002 0.00001 0.00003 
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Table 3.3 Haplotype counts (and frequency) for cases and controls determined by 
PHASE using the most probable haplotype pair as the haplotype 
assignment for an individual. 
Haplotype Case Control 
132 (0.634) 87 (0.355) 
N2 17 (0.082) 62 (0.239) 
N3 24 (0.115) 45 (0.173) 
N4 9 (0.043) 29(0.112) 
N5 6(0.029) 11 (0.042) 
N6 13 (0.063) 10 (0.038) 
N7 5(0.024) 10(0.038) 
N8 1 (0.005) 4(0.015) 
N i l 0 1 (0.004) 
N9 0 1 (0.004) 
N10 1 (0.005) 0 
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Table 3.4 Contingency table and effect size of the risk haplotype. For the OR and 
PAR, only the autosomal recessive case is considered, where cases and 
controls with two copies of the N1 haplotype are compared to those with 
zero copies. 
Copies of Risk Haplotype (Nl) O R p A R 
2 t 0 (95% CI) (95% CI) 
Case 46 (0.44) 40(0.39) 18(0.17) 10*4° °'7 1 
(4.68-23.14) (0.62-0.91) 
Control 14(0.11) 59 (0.45) 57(0.44) 
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from the HapMap database. Genotypes were uploaded into Haploview (Barrett et al , 
2005) and the LD statistics were calculated. Not all 183 of the HapMap SNPs within in 
this region were genotyped or passed the default quality control checks (Hardy-
Weinberg p-value >0.01, minimum percentage of genotyped samples >75%, maximum 
of one mendelian inconsistency and a minimum allele frequency of 0.001). Haplotype 
blocks were identified according to Gabriel et al. (Gabriel et al., 2002) and illustrated in 
Figure 3.3. 
Among the putative recombination sites revealed by the four-gamete test to surround the 
marker SNP rs 10490924, five major haplotypes, N1 - N5, inferred from nine SNPs 
(extending 63.9kb，see Figure 3.1), were identified accounting for >90% of all 
haplotypes in the sample. The odds ratio (OR) for two copies of the risk haplotype, Nl, 
is 10.40, and its 95% confidence interval (CI) overlaps with that of the single SNP 
rsl0490924, 4.68-23.14 vs. 4.83-25.69 (Table 3.1 and Table 3.4). LD was measured and 
plotted for each pair of the nine SNPs (Figure 3.2). SNP rsl0490924 appears to be in LD 
with the upstream SNPs in PLEKHA1, but the next SNP genotyped is too far 
downstream (26.3kb) to provide meaningful information about 
recombination/homoplasy breakpoints. The much denser sets of SNPs from the publicly 
available HapMap database for the Han Chinese in Beijing (CHB) population provided 
by international HapMap data did not resolve this matter, showing that rs 10490924 was 
not in LD with either gene in the region in this population (Figure 3.3). 
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Figure 3.3 Haplotype block definitions across the chromosome 10 region for the 
publicly available HapMap data from the Chinese population. Using the 
publicly available HapMap data for the Chinese population, haplotypes and 
haplotype blocks were computed and visualized in Hpaloview. Dark red 
indicates higher D' values. Light blue indicates high D，values, but LOD 
scores <2. Haplotype blocks as defined by Gabriel et al. are indicated by the 
black lines. It should be noted that of the 183 HapMap SNPs in this region, 
only 119 were available for analysis in this population. 
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H T R A 1 gene，如叩 downstream to LOC387715 (Figure 3.4), was further examined for 
its association with exudative AMD. The entire genomic region including promoters, 
exons and intron-exon junctions oiHTRAl, in search of the functional variant, were 
subsequently sequenced and presented in the following section. 
3.2. HTRA1 Genotpying 
The whole gene ofHTRAJ was sequenced by direct sequencing aiming to investigate the 
existence of genetic variants in HTRA1 contributing to the risk of exudative AMD. The 
results are reported in the following section. A total of 163 exudative AMD and 183 
controls were screened in the study. The characteristics of the study population were 
summarized in Table 3.5. The mean 士 SD age at AMD diagnosis was 75.5 土 1.5 years 
and that of controls was 73.3 士 6.5. Confounding bias of age was excluded with no age 
difference being found between the two groups. 54% of the exudative AMD cases were 
males whereas that of controls was 49.7%. No significant difference was shown in the 
sex distribution between the two groups (p二0.43). Only 153 exudative AMD cases had 
smoking status, among which 51.6% were smokers. For the 143 controls with smoking 
status, only 37.8% of them were smokers. Smoking significantly increased the risk of 
AMD 1.76-fold (p = 0.017). 
3.2.1. Association Analysis 
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Smoking associated locus 
Figure 3.4 Schematic diagram showing location of PLEKHA1, LOC387715 and 
HTRA1. The p-value and OR(95%CI) of the two SNP were obtained from 
genome-wide association study. 
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Table 3.5 Characteristics of the study population oiHTRAl screening 
Exudative AMD Controls p-value OR (95% CI) 
T o t a l 163 183 
M a l e s (%) 88 (54.0%) 91 (49.7%) ] 0.43 
Females (%) 75 (46.0%) 92 (50.3%) 
J 
Mean Age(士S.D.) (Years) 75.5 士 7.5 73.3 士 6.5 
Age Range (Years) 6 0 - 9 4 60-99 0.84 
S m o k e r 79 (51.6%) 54 (37.8%) 1 0.017 1.76 (1.11-2.80) 
Non-Smoker 74 (48.4%) 89 (62.2%) 
Missing smoking status 10 40 
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In the association analysis, the less frequent allele in the control group was considered 
the risk allele (R) and the other allele was assigned as normal allele (N). A total of 45 
sequence variants were identified in HTRA1 promoter, exons and exon-intron boundaries 
from 164 exudative AMD and 183 unrelated controls. The genotype frequency and 
summary of each variant are shown in Table 3.6. Among which 4 SNPs have violated 
H W E a n d w e r e excluded for further association and haplotype analysis, namely 
IVS5+76delGTTT, IVS6+111G>A, IVS7+149C>G and IVS8-36C>T. 
For the remaining 41 SNPs, x2 statistics of both allele and genotype frequencies were 
assessed for association to AMD risk. Fifteen variants were found only in one control 
while six variants existed in only one AMD case. These 21 rare variants were excluded 
in subsequent association analysis. 340G�C (Arg59Pro) was found heterozygously in 
both AMD and control each with only one case. This leaves 18 SNPs for further 
association analysis. Their allele and genotypic frequencies assessment were illustrated 
with calculated ORs and p-value in Table 3.7 and Figure 3.5. Allele and genotype 
frequencies of 7 out of the 18 variants were significantly associated conferring exudative 
AMD (Table 3.7). 162delCinsTCCT was just marginally associated (p=0.001) after 
Bonferroni correction. This variant was found heterozygously in 2 AMD and 16 controls. 
After Bonferroni correction (p =0.05/41 二0.001)，four variants still remained 
significantly associated with exudative AMD. They lie in the promoter and the first exon 
of HTRA1, -491G>A (rsl 1200638), -359T>C (rs2672598), 230C>T (rsl049331) and 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.7 Allelic and genotypic significant assessment ofHTRAl variants in 
exudative AMD 
HTRA1 Sequence Variants Allele Genotype 
OR 95% CI p-value p-value 
1 rsl 1200638 -497G>A* 3.337 2.423-4.596 5.9xl014* 2.97xl012* 
2 - -374C>T 1.838 0.848-3.987 0.12 0.11 
3 - -369C>T 1.829 0.54-6.189 0.39 0.32 
4 rs2672598 -359T>C* 4.611 2.909-7.307 5.0xl012* 5.04xl0"10* 
5 - 163delCinsTCCTA 7.451 1.7-32.658 0.001A 0.001A 
6 - 187C�T 1.335 0.872-2.044 0.18 0.17 
7 rsl049331 230C>T* 3.286 2.387-4.522 1.14xl0"13* 5.66xl0'12* 
8 rs2293870 236G>T* 3.286 2.387-4.522 l.HxlO'13* 5.66x10"12* 
9 rsl2267142 IVS1-176C>G# 2.023 1.056-3.873 0.031# 0.22# 
1 0 - IVS2+1000T 3.631 0.766-17.225 0.11 0.23 
11 - IVS2+317C>T 2.239 0.202-24.81 0.60 0.60 
12 rs2239586 IVS3+93C>T 1.188 0.869-1.624 0.28 0.53 
13 rs2239587 IVS3+167G>A 1.188 0.869-1.624 0.28 0.53 
14 rs2672582 IVS4+99C>T 1.209 0.894-1.635 0.22 0.22 
15 rs2672583 IVS5+169G>A# 1.347 0.996-1.822 0.053# 0.09# 
16 rs2672585 IVS6+115C>G 1.207 0.892-1.633 0.22 0.22 
17 rsl 1538140 1449C>T 1.500 0.356-6.328 0.73 0.58 
18 rs2272599 IVS8+14G>A 1.225 0.906-1.656 0.187 0.12 
* T h e s e 4 SNPs remain significantly associated with AMD after Bonferroni correction (0.05/18/2=0.001). 
This variant is marginally significant with 2 heterozygous carriers in AMD and 16 hetrozygous carriers in controls. 
# These 2 SNPs become insignificantly associated with AMD after Bonferroni correction. 
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(a) HTRA1 
Promoter and exon 1 region ofHTRAl gene 
C K D E H m ^ K M " ! I 
Intron 2, Exon 2 and intron 3 c “‘ . ^  , T 
Exon 4，Intron 4, Exon 5, Intron 5，Intron 6, 
• Intron 7, Exon 8，Intron 8 and Exon 9 
(b) 14 1 








• Bonferroni adjusted 
significant threshold 
2 
• p = 0.05/41 
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Position (kb) 
Mgure 3.5 Schematic view of the association of exudative AMD with 41 variants across a 54 
Mb region on chromosome 10 in HTRA1 gene. The position for each SNP is 
given on a kilobasepair scale, (a) Location of exons of HTRA1 that map to the 
interval, (b) -log (p) is plotted against the chromosomal location of the 41 
variants identified. 
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respectively. 230G>T and 236G>T are in perfect LD, where Z)=l and are synonymous 
variants with no amino acid change (Ala34Ala and Gly36Gly, respectively). The 
magnitude of the effect of these 4 extremely significant variants was estimated by odds 
ratio (ORs) in different models (dominant, recessive, heterozygote and homozygote) and 
population attributable risks (PARs). Table 3.8 summarizes the analyzed effects. Both 
dominant and recessive models showed significant association with AMD in all of these 
4 SNPs. In addition, an allele-dosage effect appeared to be present in all these 4 SNPs. 
Carriers of two risk alleles were at substantially higher risk (about 4 times higher) to 
exudative AMD than are carriers with one risk allele, the ORhet and ORh o m for the 4 
SNPs were 1.73 vs. 7.64，6.35 vs. 25.79, 1.76 vs. 7.56 and 1.76 vs. 7.56, respectively 
(Table 3.8). Two significant SNPs were in the promoter region, -497G>A and -359T>C 
and the other 2 SNPS were in exon 1 of HTRAL With the observed increased risk in 
carriers of the two risk alleles of these SNPs, the PARs were also found to have 
increased in similar fashion. PAR estimates at -497G>A, 230C>T and 236G>T 
increased from 24% to 55% with heterozygous and homozygous genotypes, respectively 
(Table 3.8). Relative high frequency of the risk (C) genotype at —359T�C，rs2672598, in 
the case/control sample (AMD: 84.8%; Controls: 53.0%) was observed suggesting an 
overestimation of the corresponding attributable risk, and so does not provide a good 
estimate of the risk in the population. The OR of this SNP was also inflated with ORhet 
being 6.35 95%CI (0.08-50.18) and ORhom being 25.79 95%CI (3.39-196.46). The 
observed relatively high frequency of the risk genotype was TT: 0.6%; TC: 14.6%; CC: 
84.8% for exudative and TT: 9.87%; TC: 37.2%; CC: 53.0% for controls. The single 



















































































































































































































































































































































































































































































































the promoter, -497G>A, which was the same SNP (rsl 1200638) identified in the whole 
genome association study. 
3.2.2. Haplotype Analysis 
LD analysis revealed three regions of linkage disequilibrium in HTRA1 gene (Figure 
3.6). Three haplotype blocks were constructed with Haploview (Barrett et al., 2005). 
Only the first haplotype block that lies in the promoter and exon one region was 
significantly associated predisposing exudative AMD. Five SNPS are within the block 
namely，-491G>A (rsl 1200638), -359T>C (rs2672598), 187C>T, 230C>T (rsl049331) 
and 236G�T (rs2293870). The haplotype frequencies of the block were shown in Table 
3.9 with ACCTT and GTCCG being significant AMD-predisposing haplotypes with p= 
6.68 x 10" and 4.97 x 10"12, respectively. This haplotype block contains the four 
significant variants identified in the single SNP association analysis mentioned earlier. 
After permutation, these two haplotypes remained exceptionally significant, further 
supported this region being associated to exudative AMD as in single SNP analysis. 
Haplotype block 2 contains only 2 SNPs that are in intron 3. Haplotype block 3 spans 
from intron 4 to intron 8. Both haplotype block 2 and 3 were not associated with risk of 
exudative AMD. 
3.2.3. rsl 1200638 - Smoking Interaction 
Logistic regression modeling was used to build a model of the joint contribution of 
HTRA1 and cigarette smoking, and HTRA1 and CFH. rsl 1200638 of HTRA1 and 






































































































































































































































































































































































































































































































































































































































































































































































































































































































were the most significant SNPs associated with exudative AMD in single SNP analysis. 
The risk G allele of rs800292 was found to be at 2.5 times higher risk to AMD in our 
previous study (Chen et al., 2006). Table 3.10 summarizes the best fit and parsimonious 
model analyzed by logistic regression. 
Smoking is one of the most significant environmental risk factor for AMD. Results from 
logistic regression suggested that the joint effects of smoking and rsl 1200638 ofHTRAl 
was best described by independent multiplicative effects, without significant dominance 
nor interacting effects (Table 3.10). Independent multiplicative effect is the additive 
effect on the log-scale. This model yielded the lowest AIC (AIC=367.5). The second 
best fit model was the independent multiplicative effect of rsl 1200638 at HTRA1 alone 
with no smoking effect and yielded an AIC of 369.9. The AIC difference between these 
two models was 2.4 (AIC diff > 2); hence, by definition the most best fitted and 
parsimonious model was the joint independent multiplicative effect (or independent log-
additive effect) of smoking and rsl 1200638 of HTRAL 
Given the evidence of independent multiplicative joint effects of smoking and HTRA1, 
the combined effect of smoking and 7-rsl 1200638 was further illustrated by the 
joint ORs shown in Table 3.1 la and b. The risk of AMD due to the risk genotype was 
increased with smoking. Estimates from this model demonstrated a 15.71 fold increased 
risk to exudative AMD in homozygote carriers of the HTRAl-risk allele who were ever-
smokers compared with non-smokers with no risk alleles at HTRAJ-rsl 120063S. The 
heterozygote ever-smoking carrier of the HTRAl-risk allele was 4.80 times more likely 
to be exudative AMD. The adjusted OR of smoker with non-risk allele was calculated to 
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Table 3.10 Results of fitting two factor models by logistic regression. 
Two-Factor Model AIC ^ ^ 
Difference 
HTRAl:rsl 1200638 (Factor 1) and Smoking (ever vs. never) 
工 � A D D 1 # 369.9 2 .4� 
• | 1 SMOKE 408.2 40.7 
^ DOM1 405.9 38.4 
. ^ J ADD1 - SMOKE# 367.5 (f 
O J 
^ L DOMl - SMOKE 402.7 35.2 
§ ADD*SMOKE-INT 400.1 32.6 
DOM*SMOKE-INT 413.8 46.3 
I [ ADD-DOM-SMOKE-INT 402.1 34.6 
HTRAl:rsl 1200638 (Factor 1) and CFH:rs800292 (Factor 2) 
ADD1 432.2 13.2 
| ) J ADD2 466.7 47.7 
I DOML 471 .0 52 .0 
� D O M 2 476.1 57.1 
I J A D D 1 + A D D 2 # 419.0 0# 
^ 1 DOM1+DOM2 465.5 46.5 
§ [ ADD1*ADD2-INT 461.5 42.5 
I < ADD*DOM-INT 448.9 29.9 
(D • 
S ALL-INT 448.7 29.7 
V 
AIC difference is the difference from the AIC of the best fitting model. 
# is the most parsimonious and best fit model in both interaction analysis. Model 
with best fit (lowest AIC) has AIC difference = 0. 
� i s the second best-fit model and gives an AIC difference of 2.4. This model is 
contributed by the multiplicative effect of HTRA1 only. 
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Table 3.11a Genotype distribution of rsl 1200638 in HTRA1 and smoking 
in exudative AMD (ever vs. never smoked). 
Smoking status 
HTRA1 Never Ever Never Ever 
(rsll200638) ~~ 
Controls (n=143) Exudative AMD (n=153) 
GG 30 (2.1%) 15 (10.5%) 6 (3.9%) 11 (7.2%) 
GA 44(30.8%) 25 (17.5%) 25 (16.3%) 24 (15.7%) 
AA 15(10.5%) 14(9.8%) 43 (28.1%) 44 (28.8%) 
Table 3.11b Joint ORs and 95% CI of rsl 1200638 in HTRA1 and smoking. 
OR (95% CI) 
HTRA1 ncontrois = 143 Smoking status 
rsl l200638 HamD=153 
Never Ever 
ORsmoke 1.0 (Ref) 1.76(1.11-2.80) 
PARsmoke 12.2 
PARhtra i 53.1 
Main Effects PARjoint 68.7 
ORhtrai Joint effects 
GG 1.00 (Ref) 1.00 (Ref) 3.67(1.14-11.84) 
GA 1.88 (0.96-3.66) 2.84 (1.04-7.76) 4.80 (1.70-13.58) 
AA 7.94 (3.95-15.97) 14.33 (4.99-41.18) 15.71 (5.43-45.49) 
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be 3.67. This indicated about 5-fold increase risk of smoker with homozygous risk allele 
than that with no risk allele (Table 3.11b). Corresponding ORs for smoker and non-
smoker homozygous risk-allele carrier of//77L47-rsl 1200638 were similar (15.71 and 
14.33, respectively). This indicated that the risk allele of 7-rsl 120638 exerted a 
stronger effect on AMD-risk than the effect of smoking. 
Population attributable risk (PAR) percentage was calculated to be 12.2% for smoking, 
53.1% ioxHTRAl, and 68.7% for the joint gene-environment effect (Table 3.1 lb). There 
was an observable increase PAR (about 5.5-fold increased) of the joint effect of smoking 
and HTRA1 risk-allele, indicating homozygote risk allele smoker has a substantial higher 
likelihood of developing exudative AMD in the population basis. 
3.2.4. rsl 1200638 — rs800292 Interaction 
Gene-gene interaction analysis on different models of the two variants on HTRA1 and 
C F H showed no evidence of interaction in developing exudative AMD. These two 
variants contributed independently to the disease risk. The best fit and most 
parsimonious model for their joint effect was best described by independent 
multiplicative model (independent log-additive effect) with no dominance nor 
interaction effects, yielding the lowest AIC of 419.0 (Table 3.10). The second best fit 
model only involved the main additive effect of HTRA1 alone (single gene effect) and 
gave an AIC of 432.2. The AIC difference between these two models was much greater 
than 2 (AIC difference = 13.2 as shown in Table 3.10). By definition, this model was not 
better than the lowest AIC model. The interaction analysis suggested the two genes 
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together contributed to the disease risk in an independent multiplicative manner, 
corresponding to a linear additive model on a logarithmic scale, with no interaction 
being the best-fitted and parsimonious model. 
Given the evidence of independent multiplicative effect of the two variants in HTRA1 
and CFH observed in the model comparison, corresponding ORs of AMD for each 
possible combination of the genotypes from the two variants were estimated and shown 
in Table 3.12a and b. The risk allele of rsl 1200638 at HTRA1 was the A allele where as 
that of rs800292 at CFH was the G allele. The ORs were compared with the baseline 
genotype of the two genes that showed the lowest frequency of the disease risk alleles 
(homozygote G carrier of HTRA1 with homozygote A carrier of CFH). Frequency of 
homozygous risk genotype at both loci was 5 times lower in the control (6.56%) than in 
the cases (34.36%) as shown in Table 3.12a. A joint disease odds ratio of 23.3 for 
individuals with homozygous risk alleles at both loci was observed when compared with 
the baseline wild-type (non-risk) genotype (Table 3.12b), with a wide range of 
calculated 95%CI being 2.49 to 218.24. Individuals being homozygote for HTRAl-risk 
(A) allele and any genotype for CFH-risk allele (for the AA-GA joint genotype, OR 7.63; 
AA-AA joint genotype, OR 6.43) were at higher AMD risk than those being 
homozygote for CFH-risk allele and any genotype for HTRAl-risk allele (for the GA-
GG joint genotype, OR = 3.95; and GG-GG joint genotype, OR 二 2.63) (Table 3.12b). 
The homozygous risk genotype of HTRA1 appeared to exert 2-fold stronger risk than 
that of CFH in the joint multiplicative model conferring exudative AMD. The HTRA1-
risk allele revealed a stronger impact to the development of exudative AMD than CFH-
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Table 3.12a Genotype distribution of rsl 1200638 in HTRA1 and rs800292 
in CFH in exudative AMD. 
Genotype at rs800292 in CFH 
S ^ p e a t Controls (n = 183) AMD (n = 163) 
(rsll200638) AA AG GG AA AG GG 
G G 5 31 19 1 7 10 
(2.73%) (16.9%) (10.38%) (0.61%) (4.29%) (6.13%) 
GA 17 35 38 3 18 30 
(9.29%) (19.13%) (20.77%) (1.84%) (11.04%) (18.40%) 
AA 7 19 12 9 29 56 
(3.83%) 10.38%) (6.56%) (5.52%) (17.79%) (34.36%) 
Table 3.12b Joint ORs and 95% CIs ofrs800292 in CFH and rsl 1200638 
in HTRA1 
OR & 95% CI for 
Main Effects nControis=183 CFH rs800292 
nAMD=163 A A A G G G 
ORCFH 1.0 (Ref) 1.09 2 .14 
(0.60-1.97) (1.18-3.86) 
P A R CFH 41.2 
PARHTRAI 54.9 
HTRA1 
rsl 1300638 P A R j o i n t 7 8 . 4 
ORHTRAI Joint Effects 
GG 1.00 (Ref) 1.00 (Ref) 1.13 2.63 
(0.11-11.24) (0.27-25.71) 
GA 1.88 0.88 2.57 3.95 
(0.96-3.66) (0.074-10.46) (0.28-23.70) (0.44-35.62) 
AA 7.94 6.43 7.63 23.3 
(3.95-15.97) (0.61-68.31) (0.83-70.52) (2.5-218.2) 
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risk allele. The plot of the two-locus genotype specific AMD risks on Figure 3.7 further 
illustrates the stronger impact of HTRA1 on our study exudative AMD subjects. 
Population attributable risk percentage was estimated to be 41.2% for CFi/-rs800292, 
54.9% for HTRA1-rsl\20063S, and 78.4% for the joint effect as shown in Table 3.12b. 
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Figure 3.7 Two-locus (HTRA1 and CFH) genotype specific AMD risks. 
2 5 i ‘ I f ® ] 
Odds . . . 
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4.1. Genome-wide Association Study of Exudative AMD 
Previous studies showed that CFH is a risk factor of AMD predominantly in Caucasians 
and not in Chinese and Japanese. The racial difference in prevalence of the C allele at 
Y402H in CFH between Chinese/Japanese and Caucasians lead to the postulation of 
another common genetic variant(s) in the genome giving rise to this complex disorder as 
suggested by the CDCV hypothesis. Genome-wide association study is an effective and 
powerful approach to explore on the existence of other genetic factors contributing to the 
development of AMD. 
In this genome-wide association study, a new genetic variant, rsl0490924, located on 
chromosome 10q26 was successfully mapped to the risk of exudative AMD using only 
about 100 cases and controls. This variant attributes to the population with large 
associated PAR of 84%. The impact of this genetic variant was extremely high 
conferring an OR of 11.1 exudative AMD. The extreme high PAR and OR identified 
conferring to the disease allow a small study group for this successful association. 
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This study had demonstrated the outstanding power of genome-wide association 
approach to identify disease susceptibility genes for complex genetic disease. In contrast 
to candidate genes studies, which select genes for study based on known or suspected 
disease mechanisms, genome-wide association studies permit a comprehensive scan of 
the genome in an unbiased fashion and thus have the potential to identify novel 
susceptibility regions (loci). Family-linkage based approaches only consider meiotic 
recombination events in the families studied while genome-wide association studies 
investigate that in a population-based. With this approach, association signals are 
localized to small regions of the chromosome containing only a single to a few genes, 
enabling rapid detection of the actual disease susceptibility gene. 
rsl0490924 lies in a hypothetical gene, LOC387715, residing between PLEKHA1 and 
HTRA1 (Figure 3.5). LOC387715 has no evidence of known biological function. It is 
identified to be highly expressed in placental tissue and an extremely low expression in 
the retina (Jakobsdottir et al., 2005;Rivera et al” 2005). After publication of this wide-
genome association data in 2006, numerous studies consistently replicated the 
association of this susceptible SNP to risk of AMD in both exudative AMD and 
geographic atrophy (GA). The relative risk of LOC387715-rs 10490924 and AMD found 
in each subsequent study was ranged from 3.0 with GA to 29.3 with mixed advanced 
AMD as shown in Table 4.1 and Figure 4.1. Comparing with other subsequent studies, 
the present study yielded the highest risk (OR=11.14) to exudative AMD. The risk of 
this SNP to GA yielded a much lower risk ranging from 3.0 to the maximum risk being 
7.9-fold (Francis et al” 2007). The mixed advanced AMD has yielded the highest risk of 
80 
Table 4.1 Comparisons of the odds ratio of LOC387715 at rsl0490924 to the risk 
advanced AMD among the present study and subsequent follow-up studies by 
other groups. 
AMD Grade ORhom 95% CI Cases Controls References 
Exudative 11.14 4.83-25.69 96 130 Present study 
AMD 
Advanced 5.73 3.07-10.71 610 259 (Schmidt et al., 2006) 
AMD 
Exudative 6.1 3.3-11.2 122 463 
AMD 
Geographic 3.0 1.4-6.5 69 463 (Seddon et al., 2007) 
Atrophy 
Exudative 10.0 4.3-23.3 241 280 
AMD 
Geographic 7.9 2.9-21.0 147 280 
A t r o p h y (Francis et al., 2007) 
Mixed 29.3 11.4-75.6 142 280 
advanced 
AMD 
Exudative 10.12 5.12-20.01 227 329 
AMD 
Geographic 6.43 3.00-13.79 172 329 (Ross et al., 2007) 
Atrophy 




Figure 4.1 Schematic comparisons of the association of rsl0490924 at LOC387715 
to the risk of age-related macular degeneration among the present study 
and follow-up studies by other groups. The odds ratios (OR) of 
homozygotes for each study corresponds to the center of the box, and the 
95% confidence intervals (CI) are represented by the horizontal lines 
through the boxes. 
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29.3 with a wide range of 95% CI (11.4-75.6). These subsequent studies further 
supported the finding of rsl0490924 at LOC387715 being associated not only with 
exudative AMD but also with geographic atrophy. 
The frequency of the risk T alleles at rsl0490924 was higher in exudative AMD than in 
controls, as was found in Caucasians (Francis et al., 2007;Ross et al., 2007;Schmidt et 
al” 2006;Seddon et al., 2007;Shuler, Jr. et al., 2007) and Japanese (Tanimoto et al., 
2007). Since this hypothetical gene has no known biological function, further study is 
required to determine its biological function so as to assess its role in the etiology of 
exudative AMD. This SNP can also be a surrogate SNP. Variants in LD with this SNP 
need to be evaluated for their association with exudative AMD. The frequency of the 
risk allele at PLEKHA1, located near to LOC387715, has reported to exhibit no 
difference in the Caucasians (Fisher et al., 2006;Rivera et al” 2005). Hence, the other 
nearby gene, HTRA1, requires further investigation to identify its role to the 
development of exudative AMD. 
This genome-wide association study has demonstrated its power to be effectively and 
comprehensively in testing and revealing genetic variation across the genome for a role 
in common disease. The cause of AMD, a multifactorial disease, is best described by the 
CDCV hypothesis in which multiple modest variants together play a role in developing 
this common disease. We have clearly identified the involvement of a new variant in 
HTRA1 in AMD, adding a new piece to the puzzle of how genetic factors predispose the 
complex disease. This powerful approach would also facilitate in the identification of 
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more genetic factors in molecular classification of various subtypes of AMD, such as 
polypoidal choroidal vasculopathy (PCV) and retinal angiomatous proliferations (RAP). 
4.1.1. Limitations and Concerns of Genome-Wide Association Study 
Although this study has demonstrated the success and power of genome-wide 
association study approach in identifying novel susceptible disease locus/gene, there are 
a number of limitations that need to be addressed. Genetic heterogeneity of the sample 
population is one of the important factors to be considered for spurious association. 
Population substructure can lead to false conclusions so as racial difference. It is 
essential to replicate association findings in other ethnic population to confirm any 
conclusions, especially when only modest effects of the variants are observed. MAF of 
Y402H at CFH is extremely low (0.04) to detect any significant association to AMD in 
Chinese and Japanese populations. The observed high prevalence of the risk C allele of 
Y402H at CFH in the Caucasians revealed the effects of racial difference. Most common, 
complex genetic disorders do not reflect a single model, but result from contribution of 
various mechanisms. Under these circumstances, the extent of common variants relating 
to the common, complex disorder is based not only on the disease itself and the relevant 
genes but also on the particular population that are studied. To further support the 
findings of this study, replications need to be done in other ethnic populations and was 
successfully done be subsequent investigations by other researchers as mentioned earlier. 
There is a need to adjust the level of significance to account for the large number of 
variants that are tested and use a highly stringent criterion for concluding the result. This 
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is necessary for eliminating any spurious association due to inflation of type 1 error in 
multiple testing in a genome-wide association study. 
Another key component for genome-wide association study approach is sufficient 
sample size so as to attain enough power to detect genes of modest risk to the disease. 
Power studies have shown that at least 2000 to 5000 samples for both cases and controls 
are required for genome-wide association study with modest risk (Odds Ratio about 1.2-
1.5) to successively identify the disease-predisposing variants (Pfeiffer and Gail, 
2003;Risch and Merikangas, 1996). The present study has only worked on 100 cases and 
controls and was able to detect the strong association. This was mainly due to the 
distinctively high prevalence of the risk C allele found in the disease (Minor allele 
frequency [MAF]二0.59) and its strong association to the risk of disease (LOC387715-
rsl0490924: ORhom二 11.14; 95%CI [4.83-25.69]). In a general modest associated variant, 
a large recruitment of cases and controls will be necessary. The recruitment of large 
cohorts for genome-wide association study is a challenge for collecting cases with 
consistent clinical phenotype. To recruit a large number of pedigrees in linkage studies, 
each containing multiple affected individuals especially for diseases of old age such as 
AMD is nevertheless as difficult as the recruitment of large cohorts. 
4.2. HTRA1 Genotyping 
4.2.1. Association and Haplotype Analysis 
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Age-related macular degeneration is the leading cause of visual impairment in the 
elderly and a major cause of blindness in the developed countries. Recently, CFH was 
identified as the major associated gene leading to the advanced stage of the disease. In 
this study, HTRA1, being suspected to be associated with exudative AMD, was screened 
for its association. Two variants in the promoter and two variants in the exon 1 were 
identified to be associated with exudative AMD. Carrier of the risk allele (AA) of the 
most significant SNP, rsl 1200638，being at the promoter increased the risk to exudative 
AMD with an OR of 7.9. This significant finding was replicated by another case control 
study of exudative AMD patients in Japanese population that demonstrated the 
association of HTRA1 promoter polymorphism, rsl 1200638，to exudative AMD with an 
OR of 10.1 (Yoshida et al., 2007). Consistent significant association of rsl 1200638 to 
risk of the two advanced forms of AMD, GA and exudative AMD, was also identified in 
subsequent study in Caucasians (Cameron et al” 2007). Replications of the association 
of rsl 1200638 at HTRA1 with AMD in other ethnic population further support the 
significance of HTRA1 in AMD development and progression. 
1200638 risk allele is common in the Chinese population, with 20% of 
controls having homozygous risk allele (Table 3.11a). This group of controls carrying 
two copies of the HTRA1 risk allele has higher risk to develop AMD at a later period of 
time and will require close monitoring of any signs of manifesting advanced AMD for 
early detection and treatment. 
rsl 1200638 lies 512bp upstream of the HTRA1 transcription start site and resides within 
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putative binding sites for the transcription factors, adaptor-related protein complex 2 
alpha (AP2a) and serum response factor (SRF) (Dewan et al., 2006). The presence of 
the risk allele was predicted to alter the binding affinity of AP2a and SRF, which is 
expected to disturb the expression of HTRA1 in certain extent. This genotype-driven 
expression pattern was demonstrated by the observation of an increase trend of 
luciferase expression in HTRA1 promoter-driven constructs in the AA risk genotype-
bearing constructs than the GG carriers in transfected RPE and HeLa S3 cells (Dewan et 
al.，2006). Another study has shown a stronger immunohistochemistry results in the 
drusen and along Bruch's membrane of AMD patients and an elevated expression of 
HTRA1 mRNA and protein to be associated with the AA risk genotype carrier of AMD 
patients (Cameron et al., 2007;Yang et al., 2006). These subsequent findings supported 
our result that AA risk carrier of rsl 1200638 at HTRA1 in the promoter was associated 
with risk of exudative AMD by upregulating the expression oiHTRAl. The role of 
genotype-driven increase expression of HTRA1 leading to the development of exudative 
AMD remains speculative. The possible function of HTRA1 will be discussed in the 
following section so as to postulate its possible role to the pathogenesis of exudative 
AMD. 
4.2.2. HTRA1 
MtrAl (High temperature requirement) is a member of heat shock serine proteases and is 
upregulated by cellular stress like oxidative stress in the course of degeneration. It is 
involved in arthritis, cell growth, unfolded stress response, programmed cell death 
(apoptosis), and aging. It belongs to HtrA protein family and is a secreted protein. It is 
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characterized by catalytic activity and reversible zymogen activation (Ehrmann and 
Clausen, 2004). Its N terminus is homologous to Mac25 (the Insulin-like growth factor-
binding domain, IGFBP) with a conserved Kazal-type serine protease inhibitor (KI) 
motif, and C-terminal has a PDZ domain (Figure 4.2). This Mac25/IGFBP is a 
follistatin-like protein (also, activin-binding protein) involving in proteolytic activity in 
releasing IGF from IGF-binding proteins (Zumbrunn and Trueb, 1996;Zumbrunn and 
Trueb, 1997). It has also been demonstrated to have tumor suppressive activity by 
suppressing growth in several tumor cells, such as sarcoma cells, cervical carcinoma 
cells, and embryonic carcinoma cells (Kato, 2000). This suggests that HtrAl might be 
involved in cell growth regulation by modulating the response to the growth factors 
targeted by the mac25 domain. The linker region and the SP domain bind to 
transforming growth factor Tgfp family members, regulating the extracellular matrix 
(ECM) (Kresse and Schonherr, 2001;0ka et al., 2004). Secreted HtrAl may bind to 
ECM around the cell, become fully active and subsequently, inhibit Tgfp signaling 
arising from the proteolytic activity of HtrAl. 
The diverse multiple roles of HTRA1 have been evaluated from numerous studies, yet 
still no specific biological functional can be concluded. The knowledge of the 
differential cell and tissue-specific pattern of expression of HTRA1 in normal human 
tissues reflect some insights of its possible role in the etiology of exudative AMD. Its 
observation of down-regulation in several human tumors, such as ovarian cancer 
(Bowden et al” 2006;Chien et al” 2004;Shridhar et al” 2002) and melanoma (Baldi et al., 
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Figure 4.2 Schematic representation of the protein domain ofHTRAl 
(a) Genomic view 
(b) cDNA view 
(c) Protein domains of HTRA1 
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2002) suggested its possible role in cell homeostasis. Another study reported an increase 
expression of HtrAl inhibiting in vitro proliferation and in vivo tumor growth, 
suggesting tumor suppressor function of HtrAl (Baldi et al” 2002). Some data also 
suggested that HtrAl regulating cell death involving in chemotherapthy-induced 
apoptosis (Chien et al” 2006). Many other reports proposed the secretary function of 
HtrAl to be involved in the extracellular space. Elevated synovial HtrAl levels detected 
from rheumatoid and osteoarthritis patients resulted in the specific induction of matrix 
metalloprotease 1 (MMP-1) and matrix metalloprotease 3 (MMP-3) expression (Grau et 
al” 2006;Hu et al., 1998;Tsuchiya et al” 2005). The cleavage of extracellular proteins, 
such as fibronectin, by HtrAl stimulated MMP3 expression suggested this protease 
might be playing a role in extracellular matrix remodeling. Having extracaelluar 
localization, HtrAl was also found to be highly secreted from human mast cells (Gilicze 
et al., 2007). Contrasting to previous findings that reported an inhibitory effect of HtrAl 
on Tgfp depending on its serine protease activity (Oka et al., 2004)，the Tgfp-inhibitory 
activity of HtrAl did not inhibit mucosal mast cell differentiation. Upregulation of 
HtrAl expression was also found in the uterus and trophoblast (De et al., 2004;Hu et al., 
1998;Nie et al., 2006;Nie et al., 2003) during placental development, suggesting its 
possible role in placentation. 
There is strong evidence implicating the susceptibility oiHTRAl in the risk of not only 
in exudative AMD but also in other advanced type of AMD. The observed higher 
expression of HtrAl in arthritis individuals coincides with the same condition found in 
homozygous risk allele carrier in exudative AMD; hence, suggest a clinical history of 
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arthritis can be relevant. The proposed interaction of HtrAl with growth factors may be 
important. HtrAl may increase the amount of circulating IGF by cleavage from IGF-
binding proteins at its N-terminus. An increase of circulating IGF may result in an 
increase in vascular endothelial growth factors, which are markers for AMD 
susceptibility (Bhutto et al., 2006;Churchill et al., 2006;Tong et al., 2006a) and 
therapeutic target for exudative AMD treatment (Gehrs et al., 2006;Tong et al., 2006b). 
Inhibition of TgfJ3, a potent antiangiogenic molecule, adds further support to HtrAl,s 
role in neovascularization as observed in exudative AMD (Oka et al., 2004). Similarly, 
inhibition of TGF-mediated homeostatic functions observed in osteoarthritis may have 
implications in the atrophic development observed in early and dry AMD. 
The diverse functions of HtrAl revealed from numerous studies suggesting its 
proteolytic role in releasing IGF from IGF-binding proteins, its interaction with 
extracellular targets on C-propeptides of fibril-forming types I, II and III procollagens 
(Murwantoko et al., 2004), fibronectin (Grau et al” 2006) or proteoglycans such as 
aggrecan, decorin, fibromodulin and soluable type II collagen (Tsuchiya et al., 2005), 
resulting in important function in extracellular matrix remodeling. HtrAl appears to 
have dual roles. With its upregulation being switched by stress, it acts as a promoter of 
angiogenesis via IGF and TGF pathways giving rise to the development and progression 
to exudative AMD. In addition, overexpression of HtrAl driven by the homozygous risk 
A allele at the promoter may alter the integrity of Bruch's membrane by extracellular 
matrix remodeling, favoring the invasion of choroid capillaries as occurs in exudative 
AMD (Figure 4.3). Further functional investigation is necessary to characterize this 
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Figure 4.3 Schematic diagram showing neovascularization due to the growth of 
choroidal blood vessels into the degenerating layer of retinal pigment 
epithelial cells. (Diagram was obtained and modified from King and Suzuma, 
2000) 
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proposed mechanism in genotype-driven neovascularization observed in exudative 
AMD. 
4.2.3. Gene-Environment Interaction 
Smoking is a known risk factor of AMD. In this study, 85% of the 346 patients had 
information on smoking history. The frequencies of the risk A allele of HTRA1-
rsl 1200638 associated with AMD-risk in smokers (36.6%) and non-smokers (36.2%) 
w e r e very similar whereas that with controls in smokers (18.5%) and non-smokers 
(25.9%) were two-fold lower as shown in Table 3.11a (on page 73). Smoking appeared 
to be independent of the rsl 120063 variant in HTRA1 with no significant interaction. 
Numerous studies had reported smoking to be associated with risk of advanced AMD 
independently with no interaction with other susceptible genes studied, LOC387715, 
APOE, and CFH (Francis et al” 2007;Schmidt et al” 2005;Scott et al., 2007;Seddon et 
al.，2006b). Only one recent study had reported smoking as a modifier of LOC387715, 
an AMD-susceptible gene (Schmidt et al” 2006). Whether smoking and HTRA1 
interacted or not resulting in developing AMD, this would require sample sizes with 
smoking status to precisely identify the specific interaction estimates. Smoking has been 
reported to promote inflammatory activity with observable alteration of plasma CFH 
levels (Esparza-Gordillo et al., 2004;Seddon et al” 2006b). It is necessary to investigate 
on the targets of environmental factors (smoking) that modify gene function (HTRAT) 
which will better assess the effect of environmental exposure on HTRA1. 
In this study, the large increase of PAR percentage estimates in smoking (12%) and 
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HTRA1 (53%) to the joint effect (68.7%) (as shown in Table3.11b on page 73) 
indicating smoker carrying the risk allele will be at high risk of developing the disease. 
High prevalence of the risk A allele at 付m47-rsl 1200638 in exudative AMD 
(MAF=73.2%) and controls (MAF=44.4%) were found. This reinforces and motivates 
the necessity of modifying our lifestyle in quitting smoking and having regular eye 
examinations, especially for those high risk controls, being homozygous carrier of the 
variant, who are at higher risk in developing AMD later. 
4.2.4. Gene-Gene Interaction 
CFH Y402H is associated to risk of AMD by altering the complement system and 
promoting inflammatory activity that leads to the development of drusens found in 
AMD patients. CFH-rs800292 was used to examine gene-gene interaction between CFH 
and HTRA1. The two susceptible genes acted independently with no interaction was 
identified. The risk of CFH-rs800292 to exudative AMD (OR二2.14; 95% CI [1.18-3.86]) 
was similar to that of smoking (OR-1.76; 95% CI [1.11-2.80]) while the risk of 
HTRA 1-rsl 1200638 to exudative AMD was substantially higher (OR=7.94; 95% CI 
[3.95-15.97]) (as shown in Table 3.12b on page 76). These data supported the stronger 
impact oiHTRAl to exudative AMD than smoking and CFH in this study. The joint risk 
of CFH and HTRA1 to exudative AMD was 23.33 with 95% CI being 2.49-218.24 
(Table 3.12). CFH and HTRA1 appeared to be involved in different pathway in the 
development of exudative AMD. A recent study has reported immunohistochemical 
detection of HtrA 1 in drusen of GA patients (Cameron et al” 2007). Evidence has shown 
the Y402H at CFH being associated to risk of AMD in both GA and exudative AMD. 
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This genotype data together with the observed expression of HtrAl in drusen of GA 
patients suggest that CFH and HTRA1 contribute to the development and progression of 
advanced AMD. Although our data has shown independent effect of the two genes on 
exudative AMD, further study of interactions in prospective studies with larger sample 
sizes are required to confirm the findings. 
The high prevalence of the joint CF^-rs800292 and 7-rsl 1200638 variants 
(prevalence of homozygous for either or both variants = 82.2%; Table 3.12a on page 76) 
and their strong association to exudative AMD (Joint OR = 23.33) raises the possibility 
of population genetic test of the joint-genotype in risk prediction. The availability of the 
joint variants' genetic test may help to predict the risk of developing exudative AMD. 
The potential benefits of identifying high risk, pre-symptomatic subjects would allow 
insight into the earliest manifestations of disease and allow trials of preventive treatment 
in high-risk groups. In addition, knowledge of the substantial risk of developing AMD in 
the high-risk subjects will provide motivation for them to aware of their lifestyle such as 
stop smoking, lose weight and have regular eye examinations. Recently, variant of 
transcription factor 7-like 2 (TCF7L2) gene has been identified to confer risk of type II 
diabetes giving rise to the opportunity in launching the first predictive genetic testing on 
one's risk for developing diabetes in April, 2007 (Grant et al., 2006;Humphries et al., 
2006;Zhang et al., 2006). Although genetic testing will only suggest the perspective risk 
to the disease, present findings favor the consideration of joint-loci predictive genetic 
test of AMD in which early detection of high-risk groups would result in a more 
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favorable outcome. This would help in early detection of manifestation of the disease 
and immediate treatement to delay the disease from progression. 
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Chapter 5 
Conclusions and Future Aspects 
The work of two attempts, one by genome-wide linkage disequilibrium association study 
and the other by candidate gene screening, to search for the genetic basis of AMD was 
described in this thesis. In the genome-wide association study, a single SNP, rsl0490924, 
on LOC387715 at chromosome 10q26 was identified to be significantly associated with 
exudative AMD (p-value = 4.1 x 10"12). The odds ratio conferring the disease was 11.1 
with 95% CI being 4.83 to 25.69. The high PAR of 86% implicates the extreme high 
prevalence of the risk allele that exists in the Chinese population. Haplotype analysis 
further confirmed the significance of the SNP. Another interesting SNP in perfect linkage 
disequilibrium with rsl04090924, rsl 1200638 at HTRA1, was identified to confer high risk 
to exudative AMD, with an OR of 10.0 and PAR of 84%. Our success in obtaining a new 
AMD susceptible variant verifies the powerful approach of genome-wide association in 
studying the genetics of complex diseases. Consistent with our experiences, recently a 
variant in the TCF7L2 gene and CDKAL1 gene were identified to be associated with type II 
diabetes utilizing the same genome-wide association study approach (Owen and McCarthy, 
2007;Sladek et al., 2007;Steinthorsdottir et al., 2007). 
LOC387715 is a hypothetical gene with no known biological function. It has only been 
reported to express in the placenta and sparsely in the retina. HTRA1, residing adjacent to 
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LOC387715, was chosen for investigation of its association with exudative AMD. We 
found no disease causing variants. Instead, variants strongly associated with exuative AMD 
are identified. Variants in the promoter and the first exons oiHTRAl were identified to be 
strongly associated to risk of exudative AMD. Variants in the exons are synonymous 
changes. An interesting variant in the promoter at rsl 1200638 was found to be significantly 
associated with exudative AMD. These variants are in perfect linkage disequilibrium. 
Homozygous risk allele carrier is at 7.64-fold (95% CI of 3.98-14.66) higher risk to disease 
(p-value = 1.1 x 1010). The observed high PAR of 55% suggests that as much as half of the 
population carrying the homozygous risk allele will develop the disease. Evidence has 
shown our success in identifying an important variant in the genome being associated with 
exudative AMD. This HTRA1 variant with rsl 1200638 is the second AMD susceptible 
gene discovered. The first AMD susceptible gene, CFH, is only at 2.14-fold (95%CI 1.18-
3.86) risk to exudative AMD. The HTRA1 rsl 1200638 exerts a much higher impact than 
the CFH variant rs800292 in our Chinese exudative AMD patients. The SNP at the 
promoter of HTRA1 affects the risk of a distinct AMD phenotype, exudative AMD, which 
has shown higher prevalence in Asians than in Caucasians. Consistent replication of its 
association to exudative AMD and other advanced type of AMD, geographic atrophy 
convincingly reinforced the importance of the HTRA1 variant in the etiology of AMD 
(Cameron et al., 2007;Yang et al., 2006;Yoshida et al., 2007). CFH is involved in the 
alternative complement pathway altering the immune response results in the abnormal 
deposition of drusen as observed in GA patients. No definitive biological role oiHTRAl 
has been reported (Dewan et al., 2007). Further work should focus on the investigation of 
the physiological substrates of HTRA1 in order to reveal its biological functions and 
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activities and will provide better understanding of the molecular mechanism underlying the 
role of HTRA1 in the development of exudative AMD. 
Gene-environment and gene-gene interactions in this study showed smoking to be a major 
environment risk factor to AMD. The risk AA genotype at rsl 1200638 on HTRA1 
independently increases the risk of exudative AMD. Results of our analysis gave evidence 
that CFH and HTRA1 acted independently with no interaction in the development of 
exudative AMD. They appear to be involved in different pathways in the etiology of 
advanced AMD. Further investigation on the joint mechanisms of the two genes on 
different subtypes of AMD will assist in rational drug design and effective prognosis and 
clinical management in the future. 
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Electronic-Database Information 
The URLs for data presented herein are as follows: 
D. Clayton's Web site: http://www-gene.cimr.cam.ac.uk/clayton/software/ (for SNPHAP). 
M. Stephens' Web site: http://www.stat.washington.edu/stephens/software.html (for 
PHASE) 
GOLD Web site: http://www.sph.umich.edu/csg/abecasis/GOLD/ 
Haploview Web site: http://www.broad.mit.edu/mpg/haploview/ 
Haploxt Web site: http://www.sph.umich.edu/csg/abecasis/GOLD/docs/haploxt.html 
Ensemble web site: http://www.ensembl.org/index.html 
R statistical analysis package: http://www.r-proiect.org/ 
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